Hepatitis C — RepurpOS | OpenSourceMedicine

Disease overview

Alterations

107

Molecular (A)

100

Clinical (B–E)

Direct drugs

210

Via biomarker

149

Natural agents

Natural products

105

Merged ranked

357

With trial/literature evidence

Sources: Open Targets, ClinicalTrials.gov, DGIdb, ChEMBL, PubMed MeSH, PubMed Literature, PubMed NP, ClinicalTrials.gov NP · Pipeline phase 7 · Updated 2026-07-05

Remission & chronicity

Spontaneous remission

Spontaneous clearance in <30% of acute cases; chronic infection rarely clears without treatment (<1%/year)

Best-intervention remission

>95% cured (sustained virologic response at 12 weeks) with 8-12 week courses of direct-acting antivirals (DAAs)

Drug-free remission

—

Relapse after remission

—

Chronicity

—

Gap size

Near-zero biological gap; large access/utilization gap

Primary barrier

access

Barrier detail: Only 65% of eligible patients with private insurance received DAA treatment as of 2020; rates declining since 2019; Medicaid restrictions remain in many states; $20,000+ drug cost for generics unavailable in US

Last SoC change: 2014-2016 — DAA revolution (sofosbuvir 2013, ledipasvir/sofosbuvir 2014, pan-genotypic regimens 2016-2017); prior interferon-ribavirin standard unchanged since ~2001 with <50% efficacy and severe side effects

Remission data layers: disease_db_100 · source-locked manual data · confidence: high

Identifiers: MONDO: MONDO:0005231 · MESH: D006526 · UMLS_CUI: C0019196

Right to Try Relevance Critical

Eligibility: This disease meets the federal and state right-to-try legal standard (21 U.S.C. § 360bbb-0a and Montana SB 535): it lacks disease-modifying therapy with indication-specific FDA approval. Patients with Hepatitis C may be eligible to access investigational therapies outside of clinical trials under right-to-try frameworks.

Investigational Agents

211

Phase 3: 59, Phase 2: 93, Phase 1: 59

Most Advanced Phase

Phase 3

Highest dev. stage

Gene Targets

107

Actionable

Pipeline Compounds (Top 6)

Darapladib, Fenretinide, Albinterferon Alfa-2B, Alisporivir, Amantadine, Asunaprevir

Legal Standard: Right-to-try requires the disease lacks "adequate approved therapy for that specific disease" (not symptom-management drugs). This distinction means a disease with antidepressants available still qualifies if no FDA approval exists for THAT disease indication.

View Right-to-Try Compendium

Alterations

107 total · Types A (molecular) through E (functional)

Name	Type	Subtype	Direction	Frequency	Evidence	Sources	Links
ACE angiotensin I converting enzyme	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AFP alpha fetoprotein	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AGTR1 angiotensin II receptor type 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
APBB2 amyloid beta precursor protein binding family B member 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Antiviral Activity	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
BHMT betaine--homocysteine S-methyltransferase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BHMT2 betaine--homocysteine S-methyltransferase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CASP1 caspase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CASP12 caspase 12 (gene/pseudogene)	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CASP14 caspase 14	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CASP2 caspase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CASP3 caspase 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CASP4 caspase 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CASP8 caspase 8	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CASP9 caspase 9	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CCR2 C-C motif chemokine receptor 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CD4 CD4 molecule	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CD81 CD81 molecule	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CRBN cereblon	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CTLA4 cytotoxic T-lymphocyte associated protein 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CYP3A4 cytochrome P450 family 3 subfamily A member 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CYP3A43 cytochrome P450 family 3 subfamily A member 43	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CYP3A5 cytochrome P450 family 3 subfamily A member 5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CYP3A7 cytochrome P450 family 3 subfamily A member 7	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Cmax	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
DDRGK1 DDRGK domain containing 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
DEPDC5 DEP domain containing 5, GATOR1 subcomplex subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
DGAT1 diacylglycerol O-acyltransferase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
DNAAF9 dynein axonemal assembly factor 9	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
EPOR erythropoietin receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GHR growth hormone receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GRIN1 glutamate ionotropic receptor NMDA type subunit 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GRIN2A glutamate ionotropic receptor NMDA type subunit 2A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GRIN2B glutamate ionotropic receptor NMDA type subunit 2B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GRIN2C glutamate ionotropic receptor NMDA type subunit 2C	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GRIN2D glutamate ionotropic receptor NMDA type subunit 2D	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GRIN3A glutamate ionotropic receptor NMDA type subunit 3A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GRIN3B glutamate ionotropic receptor NMDA type subunit 3B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HMGCR 3-hydroxy-3-methylglutaryl-CoA reductase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IFNA1 interferon alpha 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IFNA2 interferon alpha 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IFNAR1 interferon alpha and beta receptor subunit 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IFNAR2 interferon alpha and beta receptor subunit 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IFNGR1 interferon gamma receptor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IFNGR2 interferon gamma receptor 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IFNL3 interferon lambda 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IFNL4 interferon lambda 4 (gene/pseudogene)	Molecular	Gene	—	—	Emerging	Open Targets	Ensembl Open Targets
IFNLR1 interferon lambda receptor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL10RB interleukin 10 receptor subunit beta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL2RA interleukin 2 receptor subunit alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL2RB interleukin 2 receptor subunit beta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL2RG interleukin 2 receptor subunit gamma	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IMPDH1 inosine monophosphate dehydrogenase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ITPA inosine triphosphatase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MERTK MER proto-oncogene, tyrosine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MMP12 matrix metallopeptidase 12	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MMP13 matrix metallopeptidase 13	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MMP14 matrix metallopeptidase 14	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MMP2 matrix metallopeptidase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MMP3 matrix metallopeptidase 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MMP8 matrix metallopeptidase 8	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MMP9 matrix metallopeptidase 9	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MPL MPL proto-oncogene, thrombopoietin receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MT-ND1 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MT-ND4L mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MT-ND5 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MT-ND6 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MYO1B myosin IB	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NABP1 nucleic acid binding protein 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NCAM1 neural cell adhesion molecule 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA1 NADH:ubiquinone oxidoreductase subunit A1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA11 NADH:ubiquinone oxidoreductase subunit A11	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA3 NADH:ubiquinone oxidoreductase subunit A3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA6 NADH:ubiquinone oxidoreductase subunit A6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFAF4 NADH:ubiquinone oxidoreductase complex assembly factor 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB2 NADH:ubiquinone oxidoreductase subunit B2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB9 NADH:ubiquinone oxidoreductase subunit B9	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFC1 NADH:ubiquinone oxidoreductase subunit C1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFS2 NADH:ubiquinone oxidoreductase core subunit S2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFS7 NADH:ubiquinone oxidoreductase core subunit S7	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFV1 NADH:ubiquinone oxidoreductase core subunit V1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFV2 NADH:ubiquinone oxidoreductase core subunit V2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFV3 NADH:ubiquinone oxidoreductase subunit V3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NOS2 nitric oxide synthase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NPC1L1 NPC1 like intracellular cholesterol transporter 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NR1H4 nuclear receptor subfamily 1 group H member 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NR3C1 nuclear receptor subfamily 3 group C member 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDCD1 programmed cell death 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PPARG peroxisome proliferator activated receptor gamma	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PPIA peptidylprolyl isomerase A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Percentage of Participants With Complete Early Virologic Response (cEVR)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
RBX1 ring-box 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
RNF7 ring finger protein 7	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SLC4A11 solute carrier family 4 member 11	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SMC2 structural maintenance of chromosomes 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SSTR3 somatostatin receptor 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SSTR4 somatostatin receptor 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SVR12 (Reinfection Not Considered Failure)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Safety - adverse event rate and profile	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
TLR7 toll like receptor 7	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TMEM87B transmembrane protein 87B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
TNF tumor necrosis factor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Tmax	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
VDR vitamin D receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
VKORC1 vitamin K epoxide reductase complex subunit 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
YWHAH tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein eta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
t1/2	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—

FDA-Approved Therapies

Phase 4 agents with regulatory approval for this indication

Drug Name	Mechanism	Type
ACETAZOLAMIDE	None	Gene-targeted
ACETYLCHOLINE		Gene-targeted
AMPHETAMINE	None	Gene-targeted
ANGIOTENSIN II	agonist	Gene-targeted
ANGIOTENSIN II ACETATE	agonist	Gene-targeted
ARGIPRESSIN		Gene-targeted
ASCORBIC ACID		Gene-targeted
ASPIRIN		Gene-targeted
ATORVASTATIN		Gene-targeted
ATORVASTATIN CALCIUM TRIHYDRATE		Gene-targeted
AZACITIDINE		Gene-targeted
AZILSARTAN KAMEDOXOMIL	inhibitor	Gene-targeted
AZILSARTAN MEDOXOMIL	inhibitor; inhibitor	Gene-targeted
BENAZEPRIL	inhibitor	Gene-targeted
BENAZEPRIL HYDROCHLORIDE	inhibitor	Gene-targeted
BENAZEPRILAT	inhibitor	Gene-targeted
BETAINE	other/unknown	Gene-targeted
BICALUTAMIDE	None	Gene-targeted
BLEOMYCIN		Gene-targeted
BUMETANIDE		Gene-targeted
BUPROPION HYDROCHLORIDE		Gene-targeted
CANDESARTAN CILEXETIL	inhibitor; inhibitor	Gene-targeted
CANDOXATRIL		Gene-targeted
CAPTOPRIL	inhibitor; inhibitor	Gene-targeted
CARBACHOL	None	Gene-targeted
CILAZAPRIL	inhibitor; inhibitor	Gene-targeted
CIPROFLOXACIN	None	Gene-targeted
CLOMIPRAMINE	None	Gene-targeted
CYCLOSPORINE		Gene-targeted
DACTINOMYCIN		Gene-targeted
DASABUVIR SODIUM MONOHYDRATE	None	Direct
DESERPIDINE		Gene-targeted
DEXAMETHASONE		Gene-targeted
DIAZEPAM	None	Gene-targeted
DICHLORPHENAMIDE	None	Gene-targeted
DIETHYLSTILBESTROL	None	Gene-targeted
DISULFIRAM		Gene-targeted
DOXORUBICIN HYDROCHLORIDE		Gene-targeted
ENALAPRIL MALEATE	inhibitor	Gene-targeted
ENALAPRILAT	inhibitor	Gene-targeted
ENALAPRILAT ANHYDROUS	inhibitor	Gene-targeted
EPIRUBICIN	None	Gene-targeted
EPOETIN ALFA		Gene-targeted
EPROSARTAN	inhibitor	Gene-targeted
EPROSARTAN MESYLATE	inhibitor	Gene-targeted
ETHOXZOLAMIDE	None	Gene-targeted
ETOPOSIDE		Gene-targeted
FLUMAZENIL	None	Gene-targeted
FLUOXETINE HYDROCHLORIDE		Gene-targeted
FOLIC ACID		Gene-targeted
FOSINOPRIL	inhibitor	Gene-targeted
FOSINOPRIL SODIUM	inhibitor	Gene-targeted
FUROSEMIDE		Gene-targeted
GENISTEIN		Gene-targeted
HYDROCHLOROTHIAZIDE		Gene-targeted
HYDROGEN PEROXIDE		Gene-targeted
IMIDAPRIL	inhibitor; inhibitor	Gene-targeted
IMIPRAMINE	None	Gene-targeted
INDAPAMIDE	None	Gene-targeted
INDOMETHACIN		Gene-targeted
INDOMETHACIN	None	Gene-targeted
IRBESARTAN	inhibitor; inhibitor	Gene-targeted
IRBESARTAN HYDROCHLORIDE	inhibitor	Gene-targeted
ISOSORBIDE DINITRATE	None	Gene-targeted
LEDIPASVIR	None	Direct
LEVODOPA		Gene-targeted
LISINOPRIL	inhibitor	Gene-targeted
LISINOPRIL ANHYDROUS	inhibitor	Gene-targeted
LOSARTAN POTASSIUM	inhibitor	Gene-targeted
MAFENIDE	None	Gene-targeted
MALATHION	inhibitor	Gene-targeted
MASOPROCOL		Gene-targeted
MECAMYLAMINE	None	Gene-targeted
MESALAMINE		Gene-targeted
METHAZOLAMIDE	None	Gene-targeted
METHOTREXATE		Gene-targeted
METHOXSALEN	None	Gene-targeted
METOPROLOL	None	Gene-targeted
MIANSERIN	None	Gene-targeted
MIFEPRISTONE		Gene-targeted
MOEXIPRIL	inhibitor	Gene-targeted
MOEXIPRIL HYDROCHLORIDE	inhibitor	Gene-targeted
NALIDIXIC ACID	None	Gene-targeted
NICOTINE	None	Gene-targeted
NICOTINE POLACRILEX		Gene-targeted
NITROPRUSSIDE		Gene-targeted
NORFLOXACIN	None	Gene-targeted
OFLOXACIN	None	Gene-targeted
OLMESARTAN MEDOXOMIL	inhibitor; inhibitor	Gene-targeted
OMBITASVIR	None	Direct
PARITAPREVIR	None	Direct
PEGINTERFERON ALFA-2B		Gene-targeted
PERINDOPRIL	inhibitor	Gene-targeted
PERINDOPRIL ARGININE	inhibitor	Gene-targeted
PERINDOPRIL ERBUMINE	inhibitor	Gene-targeted
PERINDOPRILAT	inhibitor	Gene-targeted
PHENYTOIN	None	Gene-targeted
POLYETHYLENE GLYCOL 4000		Gene-targeted
PRAVASTATIN SODIUM		Gene-targeted
PRAZOSIN	None	Gene-targeted
QUINAPRIL		Gene-targeted
QUINAPRIL HYDROCHLORIDE	inhibitor	Gene-targeted
QUINAPRILAT	inhibitor	Gene-targeted
RAMIPRIL	inhibitor; inhibitor	Gene-targeted
RAMIPRILAT	inhibitor	Gene-targeted
RESCINNAMINE		Gene-targeted
RIBAVIRIN		Gene-targeted
RITONAVIR	None	Direct
RUTIN		Gene-targeted
SARALASIN ACETATE	inhibitor	Gene-targeted
SILDENAFIL		Gene-targeted
SIROLIMUS	None	Gene-targeted
SODIUM CHLORIDE		Gene-targeted
SOFOSBUVIR	None	Direct
SPARSENTAN	inhibitor; inhibitor	Gene-targeted
SPIRAPRIL	inhibitor	Gene-targeted
SPIRAPRIL HYDROCHLORIDE	inhibitor	Gene-targeted
SULBACTAM	None	Gene-targeted
TACROLIMUS ANHYDROUS	None	Gene-targeted
TAZOBACTAM	None	Gene-targeted
TELMISARTAN	inhibitor; inhibitor	Gene-targeted
TORSEMIDE		Gene-targeted
TRANDOLAPRIL	inhibitor; inhibitor	Gene-targeted
TRANDOLAPRILAT	inhibitor	Gene-targeted
TROGLITAZONE	None	Gene-targeted
VALSARTAN	inhibitor; inhibitor	Gene-targeted
VINCRISTINE		Gene-targeted
VORINOSTAT		Gene-targeted

Therapeutics

Direct disease associations, biomarker-linked drugs, OSMF narrative-review natural agents, and merged ranking. Only agents with registry trials or published clinical literature are shown by default.

Show agents without direct trial evidence

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
DASABUVIR SODIUM MONOHYDRATE	Small molecule	Approved	Strong	100	No indexed hits View evidence CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
LEDIPASVIR	Small molecule	Approved	Strong	100	8 trials 11 Cochrane 24 Meta-analysis 110 Trial pubs 45 RCT View evidence Registry trials NCT02605304 — 12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF (TERMINATED) PHASE2 NCT01434498 — GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection (COMPLETED) PHASE2 NCT02786537 — Study of Oral Treatments for Hepatitis C (COMPLETED) PHASE4 NCT02081079 — Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 4 or 5 HCV Infection (COMPLETED) PHASE2 NCT03063723 — Dynamic Changes of Monocytes and NK Cells of CHC Patient Treated by DAAs (COMPLETED) NCT01193478 — A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (COMPLETED) PHASE1 NCT01975675 — Efficacy and Safety of Sofosbuvir/Ledipasvir ± Ribavirin in Japanese Participants With Chronic Genotype 1 HCV Infection (COMPLETED) PHASE3 NCT02413593 — Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 Infection (COMPLETED) PHASE2 Published literature Cochrane review The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis (Frontiers in public health, 2023) Cochrane review Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review (Frontiers in public health, 2022) Cochrane review Effect of sofosbuvir-based DAAs on changes in lower-density lipoprotein in HCV patients: a systematic review and meta-analysis (BMC infectious diseases, 2021) Cochrane review Efficacy and safety of ledipasvir/sofosbuvir for hepatitis C among drug users: a systematic review and meta-analysis (Virology journal, 2021) Cochrane review Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis (Journal of hepatology, 2019) Meta-analysis Efficacy and safety of direct acting antiviral regimens for hepatitis C virus and human immunodeficiency virus co-infection: systematic review and network meta-analysis (Journal of gastroenterology and hepatology, 2020) Meta-analysis Systematic Review with Meta-Analysis: Efficacy and Safety of Direct-Acting Antivirals for Chronic Hepatitis C Genotypes 5 and 6 (BioMed research international, 2019) Systematic review Cost-effectiveness of sofosbuvir- ledipasvir for Hepatitis C treatment: a systematic review (European journal of clinical pharmacology, 2026) Clinical trial publication Feasibility, safety, efficacy and potential scaling-up of sofosbuvir-based HCV treatment in Central and West Africa: (TAC ANRS 12311 trial) (Scientific reports, 2024) Clinical trial publication Statins Increase the Bioavailability of Fixed-Dose Combination of Sofosbuvir/Ledipasvir by Inhibition of P-glycoprotein (Drug research, 2022) Clinical trial publication Sustainable and equivalent improvements in symptoms and functional well-being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis C infection: Findings from the randomized PRIORITIZE trial (Journal of viral hepatitis, 2022) Clinical trial publication Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: a randomized controlled trial (Journal of medicine and life, 2022) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
OMBITASVIR	Small molecule	Approved	Strong	100	8 trials 5 Cochrane 11 Meta-analysis 77 Trial pubs 35 RCT View evidence Registry trials NCT01833533 — A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection (COMPLETED) PHASE3 NCT02786537 — Study of Oral Treatments for Hepatitis C (COMPLETED) PHASE4 NCT02615145 — Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C) (COMPLETED) NCT03341988 — Evaluation of Treatment of Chronic HCV Patients in Chronic Kidney Disease Versus End Stage Renal Disease Patients (COMPLETED) PHASE1 NCT02618928 — The Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in France (COMPLETED) NCT01995071 — A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV) (COMPLETED) PHASE2 NCT03050905 — Proof of Concept Study To Evaluate the Efficacy and Justification Of OBV/PTV/r and DSV In Adults With Chronic Hepatitis C Virus Genotype 2K/1B (COMPLETED) PHASE4 NCT03053180 — Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir (r) - Ombitasvir, + Dasabuvir Without Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis in the Russian Federation (COMPLETED) Published literature Cochrane review The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis (Frontiers in public health, 2023) Cochrane review Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review (Frontiers in public health, 2022) Cochrane review Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis (Journal of hepatology, 2019) Cochrane review Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis (Liver international : official journal of the International Association for the Study of the Liver, 2017) Cochrane review Safety of interferon-free therapies for chronic hepatitis C: a network meta-analysis (Journal of clinical pharmacy and therapeutics, 2016) Meta-analysis Efficacy and safety of direct acting antiviral regimens for hepatitis C virus and human immunodeficiency virus co-infection: systematic review and network meta-analysis (Journal of gastroenterology and hepatology, 2020) Meta-analysis Sustained Virological Response in Special Populations with Chronic Hepatitis C Using Interferon-Free Treatments: A Systematic Review and Meta-analysis of Observational Cohort Studies (Clinical drug investigation, 2018) Meta-analysis Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin for Treatment of Hepatitis C Virus Genotype 1: A Systematic Review and Meta-analysis (Clinical drug investigation, 2017) Clinical trial publication A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study (Hepatology (Baltimore, Md.), 2021) Clinical trial publication Impact of IL28B gene polymorphism on efficacy and safety of direct acting antivirals in hepatitis C Egyptian patients (International journal of clinical pharmacy, 2020) Clinical trial publication Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus-HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune Activation (The Journal of infectious diseases, 2020) Clinical trial publication High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience (Archives of virology, 2020) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
PARITAPREVIR	Small molecule	Approved	Strong	100	8 trials 5 Cochrane 11 Meta-analysis 70 Trial pubs 31 RCT View evidence Registry trials NCT01833533 — A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection (COMPLETED) PHASE3 NCT02786537 — Study of Oral Treatments for Hepatitis C (COMPLETED) PHASE4 NCT02615145 — Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C) (COMPLETED) NCT03341988 — Evaluation of Treatment of Chronic HCV Patients in Chronic Kidney Disease Versus End Stage Renal Disease Patients (COMPLETED) PHASE1 NCT02618928 — The Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in France (COMPLETED) NCT01995071 — A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV) (COMPLETED) PHASE2 NCT02068222 — A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection (COMPLETED) PHASE2 NCT03050905 — Proof of Concept Study To Evaluate the Efficacy and Justification Of OBV/PTV/r and DSV In Adults With Chronic Hepatitis C Virus Genotype 2K/1B (COMPLETED) PHASE4 Published literature Cochrane review The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis (Frontiers in public health, 2023) Cochrane review Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review (Frontiers in public health, 2022) Cochrane review Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis (Journal of hepatology, 2019) Cochrane review Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis (Liver international : official journal of the International Association for the Study of the Liver, 2017) Cochrane review Safety of interferon-free therapies for chronic hepatitis C: a network meta-analysis (Journal of clinical pharmacy and therapeutics, 2016) Meta-analysis Efficacy and safety of direct acting antiviral regimens for hepatitis C virus and human immunodeficiency virus co-infection: systematic review and network meta-analysis (Journal of gastroenterology and hepatology, 2020) Meta-analysis Direct-acting antiviral agents for liver transplant recipients with recurrent genotype 1 hepatitis C virus infection: Systematic review and meta-analysis (Transplant infectious disease : an official journal of the Transplantation Society, 2019) Meta-analysis Sustained Virological Response in Special Populations with Chronic Hepatitis C Using Interferon-Free Treatments: A Systematic Review and Meta-analysis of Observational Cohort Studies (Clinical drug investigation, 2018) Clinical trial publication A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study (Hepatology (Baltimore, Md.), 2021) Clinical trial publication Impact of IL28B gene polymorphism on efficacy and safety of direct acting antivirals in hepatitis C Egyptian patients (International journal of clinical pharmacy, 2020) Clinical trial publication Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus-HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune Activation (The Journal of infectious diseases, 2020) Clinical trial publication High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience (Archives of virology, 2020) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
RITONAVIR	Small molecule	Approved	Strong	100	8 trials 6 Cochrane 12 Meta-analysis 128 Trial pubs 60 RCT View evidence Registry trials NCT01220947 — A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection (COMPLETED) PHASE2 NCT01833533 — A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection (COMPLETED) PHASE3 NCT01323257 — TMC435-TiDP16-C115 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Erythromycin and Between TMC435 and Darunavir/Ritonavir (DRV/r) (COMPLETED) PHASE1 NCT02786537 — Study of Oral Treatments for Hepatitis C (COMPLETED) PHASE4 NCT00437476 — Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Antiretroviral (ARV) Naive Patients Starting Treatment With Anti-HCV Therapy (UNKNOWN) PHASE3 NCT02615145 — Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C) (COMPLETED) NCT03341988 — Evaluation of Treatment of Chronic HCV Patients in Chronic Kidney Disease Versus End Stage Renal Disease Patients (COMPLETED) PHASE1 NCT00023218 — Effect of a Change in HIV Therapy on Liver Steatosis, Inflammation, and Fibrosis (WITHDRAWN) NA Published literature Cochrane review The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis (Frontiers in public health, 2023) Cochrane review Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review (Frontiers in public health, 2022) Cochrane review Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis (Journal of hepatology, 2019) Cochrane review Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis (Liver international : official journal of the International Association for the Study of the Liver, 2017) Cochrane review Safety of interferon-free therapies for chronic hepatitis C: a network meta-analysis (Journal of clinical pharmacy and therapeutics, 2016) Meta-analysis Efficacy and safety of direct acting antiviral regimens for hepatitis C virus and human immunodeficiency virus co-infection: systematic review and network meta-analysis (Journal of gastroenterology and hepatology, 2020) Meta-analysis Direct-acting antiviral agents for liver transplant recipients with recurrent genotype 1 hepatitis C virus infection: Systematic review and meta-analysis (Transplant infectious disease : an official journal of the Transplantation Society, 2019) Meta-analysis Sustained Virological Response in Special Populations with Chronic Hepatitis C Using Interferon-Free Treatments: A Systematic Review and Meta-analysis of Observational Cohort Studies (Clinical drug investigation, 2018) Clinical trial publication A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study (Hepatology (Baltimore, Md.), 2021) Clinical trial publication Impact of IL28B gene polymorphism on efficacy and safety of direct acting antivirals in hepatitis C Egyptian patients (International journal of clinical pharmacy, 2020) Clinical trial publication [Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C] (Terapevticheskii arkhiv, 2019) Clinical trial publication Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus-HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune Activation (The Journal of infectious diseases, 2020) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
SOFOSBUVIR	Small molecule	Approved	Strong	100	8 trials 28 Cochrane 60 Meta-analysis 327 Trial pubs 144 RCT View evidence Registry trials NCT03158857 — Hepatitis C Treatment Study in Myanmar (WITHDRAWN) NCT03057847 — Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection (COMPLETED) PHASE4 NCT02605304 — 12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF (TERMINATED) PHASE2 NCT02786537 — Study of Oral Treatments for Hepatitis C (COMPLETED) PHASE4 NCT04948801 — SOF/VEL±RBV: Efficacy and Safety in GT 3 and 6 HCV Patients (UNKNOWN) NCT01994486 — Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1 (COMPLETED) PHASE2 NCT03809533 — The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients (ACTIVE_NOT_RECRUITING) PHASE2 NCT03369327 — Sofosbuvir and Daclatasvir for Treating Hepatitis C in 200 Patients Co-infected With Human Immunodeficiency Virus (COMPLETED) PHASE3 Published literature Cochrane review Glecaprevir/Pibrentasvir Versus Sofosbuvir/Velpatasvir for Hepatitis C Virus Genotype 6: A Systematic Review and Meta-Analysis (Reviews in medical virology, 2025) Cochrane review Efficacy and safety of direct-acting antiviral regimen for patients with hepatitis C virus genotype 2: a systematic review and meta-analysis (BMC gastroenterology, 2024) Cochrane review The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis (Frontiers in public health, 2023) Cochrane review The impact of sofosbuvir/velpatasvir/voxilaprevir treatment on serum hyperglycemia in hepatitis C virus infections: a systematic review and meta-analysis (Annals of medicine, 2023) Cochrane review Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis (Medicine, 2022) Meta-analysis Efficacy and Safety of Velpatasvir Plus Sofosbuvir With or Without Ribavirin in Hepatitis C Patients With Decompensated Cirrhosis: A Systematic Review and Meta-Analysis (Journal of viral hepatitis, 2025) Meta-analysis Efficacy of 8-week daclatasvir-sofosbuvir regimen in chronic hepatitis C: a systematic review and meta-analysis (Virology journal, 2024) Meta-analysis Prevalence of Drug Resistance Associated Substitutions in Persons With Chronic Hepatitis C Infection and Virological Failure Following Initial or Re-treatment With Pan-genotypic Direct-Acting Antivirals: A Systematic Review and Meta-analysis (Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2024) Systematic review Cost-effectiveness of sofosbuvir- ledipasvir for Hepatitis C treatment: a systematic review (European journal of clinical pharmacology, 2026) Clinical trial publication A Multicenter, open-label, randomized, non-inferiority trial of 8 versus 12 weeks of sofosbuvir/ravidasvir treatment in non-cirrhotic patients with chronic hepatitis C virus infection (EASE trial) (International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2026) Clinical trial publication Sofosbuvir/Velpatasvir/Voxilaprevir Versus Sofosbuvir/Velpatasvir Plus Ribavirin in Patients With Hepatitis C Virus Genotype 3b and Compensated Cirrhosis: A Multicentre Randomized Controlled Trial (Journal of medical virology, 2025) Clinical trial publication Long-term changes in hepatic reserve and prognosis after direct-acting antiviral treatment in patients with hepatitis C virus-related decompensated cirrhosis: a five-year follow-up study of a Japanese phase 3 trial (Journal of gastroenterology, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
ACETAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ACETYLCHOLINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMPHETAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ANGIOTENSIN II Repurposing	Small molecule	Approved	Strong	95	1 trials 2 Trial pubs View evidence Registry trials NCT03944447 — Outcomes Mandate National Integration With Cannabis as Medicine (UNKNOWN) PHASE2 Published literature Clinical trial publication Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C (American journal of physiology. Gastrointestinal and liver physiology, 2009) Clinical trial publication Therapeutic effect of ARBs on insulin resistance and liver injury in patients with NAFLD and chronic hepatitis C: a pilot study (International journal of molecular medicine, 2008) CT.gov search · Cochrane · PubMed	DGIdb	—
ANGIOTENSIN II ACETATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ARGIPRESSIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ASCORBIC ACID Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ASPIRIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ATORVASTATIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ATORVASTATIN CALCIUM TRIHYDRATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AZACITIDINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AZILSARTAN KAMEDOXOMIL Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
AZILSARTAN MEDOXOMIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BENAZEPRIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BENAZEPRIL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BENAZEPRILAT Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BETAINE Repurposing	Small molecule	Approved	Strong	95	3 trials 1 Trial pubs 1 RCT View evidence Registry trials NCT00571714 — Pilot Comparison of Standard Antiviral Therapy With and Without 12 Weeks of Betaine in Genotype 1 Naive Patients (WITHDRAWN) NA NCT00310336 — Chronic Hepatitis C Non-Responder Study With AdoMet and Betaine (COMPLETED) PHASE2, PHASE3 NCT00882193 — Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers (TERMINATED) EARLY_PHASE1 Published literature Clinical trial publication S-adenosyl-methionine and betaine improve early virological response in chronic hepatitis C patients with previous nonresponse (PloS one, 2010) CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
BICALUTAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BLEOMYCIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BUMETANIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BUPROPION HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CANDESARTAN CILEXETIL Repurposing	Small molecule	Approved	Strong	95	2 trials View evidence Registry trials NCT03770936 — Effect of Some Drugs on Liver Fibrosis (RECRUITING) PHASE3 NCT00930995 — Angiotensin Receptor Blockade as an Anti-Fibrotic Intervention in Patients With Chronic Hepatitis C (WITHDRAWN) PHASE2 CT.gov search · Cochrane · PubMed	DGIdb	—
CANDOXATRIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPTOPRIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CARBACHOL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CHEMBL269732	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
CHEMBL8	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
CILAZAPRIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CLOMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CYCLOSPORINE Repurposing	Small molecule	Approved	Strong	95	8 trials 2 Cochrane 4 Meta-analysis 43 Trial pubs 16 RCT View evidence Registry trials NCT01467505 — An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients (TERMINATED) PHASE2 NCT03665766 — Effect of Cyclosporine A Versus Tacrolimus on Response to Antiviral Therapy After Hepatitis C Genotype -4 Recurrence Post Liver Transplantation (COMPLETED) NCT01479881 — A Study in Healthy Participants Investigating the Effect of TMC435 on the Pharmacokinetics of Immunosuppressants Cyclosporine and Tacrolimus (COMPLETED) PHASE1 NCT00983060 — Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients (COMPLETED) PHASE2 NCT00284921 — MYPROMS-ES02: Safety and Efficacy of Basiliximab, Cyclosporine Microemulsion and Enteric-coated Mycophenolate Sodium (EC-MPS) Versus EC-MPS and Steroid Therapy in Kidney Transplant Recipients Who Are Hepatitis C Positive (TERMINATED) PHASE3 NCT00375895 — Switch From Tacrolimus to Cyclosporin in the Treatment of Recurrent Hepatitis C After Liver Transplantation (TERMINATED) PHASE3 NCT04113915 — Viral Hepatitis B and C Infection in Patients With Idiopathic Thrombocytopenic Purpura Treated With Triple Therapy (UNKNOWN) NCT00668369 — Effect of Immunosuppression Drug Weaning on Hepatitis C Virus (HCV)-Induced Liver Damage After Liver Transplantation (COMPLETED) PHASE2 Published literature Cochrane review Efficacy of immunosuppression monotherapy after liver transplantation: a meta-analysis (World journal of gastroenterology, 2014) Cochrane review Tacrolimus-based versus cyclosporine-based immunosuppression in hepatitis C virus-infected patients after liver transplantation: a meta-analysis and systematic review (PloS one, 2014) Meta-analysis Efficacy of antiviral therapy for hepatitis C after liver transplantation with cyclosporine and tacrolimus: a systematic review and meta-analysis (Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2013) Meta-analysis Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis (Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2007) Clinical trial publication Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients (Journal of hepatology, 2018) Clinical trial publication Pharmacokinetic Interaction between Faldaprevir and Cyclosporine or Tacrolimus in Healthy Volunteers: A Prospective, Open-Label, Fixed-Sequence, Crossover Study (Basic & clinical pharmacology & toxicology, 2018) Clinical trial publication Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study (Transplant infectious disease : an official journal of the Transplantation Society, 2017) Clinical trial publication Twice-Daily Telaprevir for Posttransplant Genotype 1 Hepatitis C Virus: A Prospective Safety, Efficacy, and Pharmacokinetics Study (Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2018) Clinical trial publication Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection (Therapeutic drug monitoring, 2016) Randomized controlled trial Sustained virological response to antiviral therapy in a randomized trial of cyclosporine versus tacrolimus in liver transplant patients with recurrent hepatitis C infection (Annals of transplantation, 2015) Randomized controlled trial REFINE: a randomized trial comparing cyclosporine A and tacrolimus on fibrosis after liver transplantation for hepatitis C (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2014) Randomized controlled trial Hepatitis C virus viral kinetics during α-2a or α-2b pegylated interferon plus ribavirin therapy in liver transplant recipients with different immunosuppression regimes (Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2012) CT.gov search · Cochrane · PubMed	DGIdb	—
DACTINOMYCIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DESERPIDINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DEXAMETHASONE Repurposing	Small molecule	Approved	Strong	95	1 trials View evidence Registry trials NCT04113915 — Viral Hepatitis B and C Infection in Patients With Idiopathic Thrombocytopenic Purpura Treated With Triple Therapy (UNKNOWN) CT.gov search · Cochrane · PubMed	DGIdb	—
DIAZEPAM Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DISULFIRAM Repurposing	Small molecule	Approved	Strong	95	1 Cochrane 1 Trial pubs View evidence Published literature Cochrane review Systematic review of the pharmacological treatment of alcohol use disorders in individuals infected with hepatitis C (Addiction science & clinical practice, 2015) Clinical trial publication Disulfiram therapy in patients with hepatitis C: a 12-month, controlled, follow-up study (Journal of studies on alcohol, 2004) CT.gov search · Cochrane · PubMed	DGIdb	—
DOXORUBICIN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ENALAPRIL MALEATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ENALAPRILAT Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ENALAPRILAT ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
EPIRUBICIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
EPOETIN ALFA Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
EPROSARTAN Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
EPROSARTAN MESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ETHOXZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ETOPOSIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
FLUMAZENIL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
FLUOXETINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
FOLIC ACID Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
FOSINOPRIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
FOSINOPRIL SODIUM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
FUROSEMIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
GENISTEIN Repurposing	Small molecule	Approved	Strong	95	1 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
HYDROCHLOROTHIAZIDE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
HYDROGEN PEROXIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
IMIDAPRIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
IMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDAPAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDOMETHACIN Repurposing	Small molecule	Approved	Strong	95	1 Trial pubs View evidence Published literature Clinical trial publication [Treatment of chronic virus hepatitis with acetylsalicylic acid] (Schweizerische medizinische Wochenschrift, 1995) CT.gov search · Cochrane · PubMed	DGIdb	—
INDOMETHACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
IRBESARTAN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
IRBESARTAN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ISOSORBIDE DINITRATE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
LEVODOPA Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
LISINOPRIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
LISINOPRIL ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
LOSARTAN POTASSIUM Repurposing	Small molecule	Approved	Strong	95	1 trials View evidence Registry trials NCT00298714 — Effects of Losartan on Hepatic Fibrogenesis in Chronic Hepatitis C (COMPLETED) PHASE4 CT.gov search · Cochrane · PubMed	DGIdb	—
MAFENIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MALATHION Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MASOPROCOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MECAMYLAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MESALAMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
METHAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHOTREXATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
METHOXSALEN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METOPROLOL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MIANSERIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MIFEPRISTONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MOEXIPRIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MOEXIPRIL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NALIDIXIC ACID Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NICOTINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NICOTINE POLACRILEX Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NITROPRUSSIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NORFLOXACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
OFLOXACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
OLMESARTAN MEDOXOMIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PEGINTERFERON ALFA-2B Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PERINDOPRIL Repurposing	Small molecule	Approved	Strong	95	1 Trial pubs 1 RCT View evidence Published literature Clinical trial publication Interferon augments the anti-fibrotic activity of an angiotensin-converting enzyme inhibitor in patients with refractory chronic hepatitis C (World journal of gastroenterology, 2006) CT.gov search · Cochrane · PubMed	DGIdb	—
PERINDOPRIL ARGININE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PERINDOPRIL ERBUMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PERINDOPRILAT Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PHENYTOIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
POLYETHYLENE GLYCOL 4000 Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PRAVASTATIN SODIUM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PRAZOSIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
QUINAPRIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
QUINAPRIL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
QUINAPRILAT Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
RAMIPRIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
RAMIPRILAT Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
RESCINNAMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
RIBAVIRIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
RUTIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
SARALASIN ACETATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
SILDENAFIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
SIROLIMUS Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
SODIUM CHLORIDE Repurposing	Small molecule	Approved	Strong	95	8 trials View evidence Registry trials NCT00800007 — Study of Safety and Tolerability of Multiple Intravenous Doses of ANZ-521 in Adults With Chronic Hepatitis C Virus (TERMINATED) PHASE1, PHASE2 NCT00990938 — Study of Combination Treatment With IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 Patients (COMPLETED) PHASE1 NCT01518933 — Effect of LEGALON SIL on Hepatitis C Virus Recurrence in Stable Liver Transplanted Patients (TERMINATED) PHASE2 NCT01459419 — Oral Administration of Anti-CD3 Monoclonal Antibody in Non-responder Genotype-I Chronic Hepatitis C Subjects (UNKNOWN) PHASE2 NCT07237282 — A Phase 1 Clinical Trial of Adjuvanted Protein-based HCV Vaccine Candidates (HCV Vaccine Trial) (NOT_YET_RECRUITING) PHASE1 NCT02340962 — Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection (COMPLETED) PHASE2 NCT00500747 — Chiron Corp HCV E1/E2 Vaccine (COMPLETED) PHASE1 NCT00728936 — Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients (COMPLETED) PHASE1 CT.gov search · Cochrane · PubMed	DGIdb	—
SPARSENTAN Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
SPIRAPRIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
SPIRAPRIL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
SULBACTAM Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TAZOBACTAM Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TELMISARTAN Repurposing	Small molecule	Approved	Strong	95	1 Trial pubs View evidence Published literature Clinical trial publication Therapeutic effect of ARBs on insulin resistance and liver injury in patients with NAFLD and chronic hepatitis C: a pilot study (International journal of molecular medicine, 2008) CT.gov search · Cochrane · PubMed	DGIdb	—
TORSEMIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TRANDOLAPRIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TRANDOLAPRILAT Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
TROGLITAZONE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
VALSARTAN Repurposing	Small molecule	Approved	Strong	95	1 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
VINCRISTINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
VORINOSTAT Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ALBINTERFERON ALFA-2B	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
ALISPORIVIR	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
AMANTADINE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
ASUNAPREVIR	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
BECLABUVIR	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
DANOPREVIR	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
DASABUVIR	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
EFAVIRENZ	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
ELBASVIR	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
ELTROMBOPAG	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
EMTRICITABINE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
EPOETIN ALFA	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
ERGOCALCIFEROL	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
FALDAPREVIR	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
INFLIXIMAB	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
INTERFERON ALFA	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
INTERFERON ALFA-2A	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
INTERFERON ALFA-2B	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
INTERFERON ALFACON-1	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
INTERFERON BETA-1A	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
LOPINAVIR	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
PEGINTERFERON ALFA-2A	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
PEGINTERFERON LAMBDA-1A	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
PRADIGASTAT	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
RILPIVIRINE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
RUZASVIR	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
SIMEPREVIR	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
VANIPREVIR	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
ALLANTOIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BEMNIFOSBUVIR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BOCEPREVIR	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
CEPEGINTERFERON ALFA-2B	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CHEMBL1255891	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL1456	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHOLECALCIFEROL	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
COBICISTAT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DACLATASVIR	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
DELEOBUVIR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ELVITEGRAVIR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
EMTRICITABINE, (+/-)-	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FURAPREVIR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
GLECAPREVIR	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
GRAZOPREVIR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
GRAZOPREVIR ANHYDROUS	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
NELITOLIMOD	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
NOVAFERON	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PEGINTERFERON ALFA-2B	Biologic	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
PIBRENTASVIR	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
RIBAVIRIN	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
ROPEGINTERFERON ALFA-2B	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SILYBIN A	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TARIBAVIRIN HYDROCHLORIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TELAPREVIR	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
TENOFOVIR ALAFENAMIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
THYMALFASIN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
YIMITASVIR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
YIMITASVIR PHOSPHATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DARAPLADIB Repurposing	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
FENRETINIDE Repurposing	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
ATORVASTATIN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
BETAINE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
CYCLOSPORINE	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
FILIBUVIR	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
FLUVASTATIN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
MERICITABINE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
MIFEPRISTONE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
MIRAVIRSEN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
NESBUVIR	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
NITAZOXANIDE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
PIOGLITAZONE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
PREDNISONE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
RALTEGRAVIR	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
RAVIDASVIR	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ROSUVASTATIN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
SAMATASVIR	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
SETROBUVIR	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
SILIBININ	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
SOVAPREVIR	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
THALIDOMIDE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
UPRIFOSBUVIR	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
VELPATASVIR	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ABT-072	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ABT-384	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ADAFOSBUVIR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ADEFOVIR DIPIVOXIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ADEMETIONINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AVATROMBOPAG	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BEMNIFOSBUVIR SULFATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BMS-986094	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CHEMBL1016	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1200574	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201482	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1569	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1617	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1908360	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CTS-1027	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EMRICASAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EZETIMIBE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GS-9256	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INTERFERON GAMMA-1B	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ISATORIBINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ISATORIBINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LOMIBUVIR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LUTETIUM OXODOTREOTIDE LU-177	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MBL-HCV-1	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MERIMEPODIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MITOQUINONE CATION	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NIM811	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NIVOCASAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ODALASVIR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PEMBROLIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PF-4136309	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PSI-352938	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RADALBUVIR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RAVIDASVIR HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RG-7795	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SCY 635	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TARIBAVIRIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TEGOBUVIR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TEMAVIRSEN SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TMC-647055	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TREMELIMUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
UT-231B	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VEDROPREVIR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VX-135	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
WARFARIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BELNACASAN Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	ChEMBL Open Targets
CHEMBL:CHEMBL265439 Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	ChEMBL Open Targets
CHEMBL:CHEMBL34833 Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	ChEMBL Open Targets
CHEMBL:CHEMBL415893 Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	ChEMBL Open Targets
EMRICASAN Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	—
GRASSYSTATIN A Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	—
PRALNACASAN Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	—
TASOSARTAN Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	—
VERMISTATIN Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	ChEMBL Open Targets
Z-VDVAD-FMK Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	—
ALPRENOLOL Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
AMIFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
BROLAMFETAMINE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
CARZENIDE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIMECAMINE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ELLAGIC ACID Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ENISOPROST Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FENCAMFAMIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FLEROXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
IDOXIFENE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
LYSERGIDE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
MERAFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
TENAMFETAMINE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ZIDAPAMIDE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ABACAVIR	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
BAVITUXIMAB	Biologic	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
BUPRENORPHINE	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
CLEMIZOLE	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
HYDROXYCHLOROQUINE	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
INTERFERON	Biologic	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
NALOXONE	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
TENOFOVIR DISOPROXIL FUMARATE	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
VESATOLIMOD	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
VOXILAPREVIR	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
4'-AZIDOCYTIDINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ALDESLEUKIN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AZD-7295	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BALAPIRAVIR	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BILB-1941	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BMS-929075	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CHEMBL1162	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL1323	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL1422	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL1503	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL1508	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL1751	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL192	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL2108518	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL2108956	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL32	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL532	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL651	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL655	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL691	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL809	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CILUPREVIR	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CPG-52852	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DELDEPREVIR	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DOLUTEGRAVIR	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ELSULFAVIRINE SODIUM	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
EPIGALOCATECHIN GALLATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ERLOTINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
FURAPROFEN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GS-6620	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GSK-625433	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
INTERLEUKIN-7	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ITX-5061	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
JTK-853	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MK-2748	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MK-3281	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MK-6325	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MK-8876	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NAMODENOSON	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NIVOLUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ROCAKINOGENE SIFUPLASMID	Gene therapy	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ST. JOHN'S WORT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TILSOTOLIMOD	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TILSOTOLIMOD SODIUM	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TIPRANAVIR	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TMC-649128	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VCH-759	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
XTL-6865	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
COLCHICINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DEXAMETHASONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
HISTAMINE DIHYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
HYDROCORTISONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LAMIVUDINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
METHYLPREDNISOLONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
METHYLPREDNISOLONE ACETATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
POLYETHYLENE GLYCOL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
POLYETHYLENE GLYCOL 3350	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
POLYETHYLENE GLYCOL 4000	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PREDNISOLONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
RIMANTADINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
RITUXIMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SILYMARIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TACROLIMUS	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TAURURSODIOL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TENOFOVIR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TRIAMCINOLONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TRIAMCINOLONE ACETONIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
URSODIOL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
DASABUVIR SODIUM MONOHYDRATE	Small molecule	Approved	Strong	100	No indexed hits View evidence CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
LEDIPASVIR	Small molecule	Approved	Strong	100	8 trials 11 Cochrane 24 Meta-analysis 110 Trial pubs 45 RCT View evidence Registry trials NCT02605304 — 12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF (TERMINATED) PHASE2 NCT01434498 — GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection (COMPLETED) PHASE2 NCT02786537 — Study of Oral Treatments for Hepatitis C (COMPLETED) PHASE4 NCT02081079 — Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 4 or 5 HCV Infection (COMPLETED) PHASE2 NCT03063723 — Dynamic Changes of Monocytes and NK Cells of CHC Patient Treated by DAAs (COMPLETED) NCT01193478 — A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (COMPLETED) PHASE1 NCT01975675 — Efficacy and Safety of Sofosbuvir/Ledipasvir ± Ribavirin in Japanese Participants With Chronic Genotype 1 HCV Infection (COMPLETED) PHASE3 NCT02413593 — Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 Infection (COMPLETED) PHASE2 Published literature Cochrane review The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis (Frontiers in public health, 2023) Cochrane review Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review (Frontiers in public health, 2022) Cochrane review Effect of sofosbuvir-based DAAs on changes in lower-density lipoprotein in HCV patients: a systematic review and meta-analysis (BMC infectious diseases, 2021) Cochrane review Efficacy and safety of ledipasvir/sofosbuvir for hepatitis C among drug users: a systematic review and meta-analysis (Virology journal, 2021) Cochrane review Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis (Journal of hepatology, 2019) Meta-analysis Efficacy and safety of direct acting antiviral regimens for hepatitis C virus and human immunodeficiency virus co-infection: systematic review and network meta-analysis (Journal of gastroenterology and hepatology, 2020) Meta-analysis Systematic Review with Meta-Analysis: Efficacy and Safety of Direct-Acting Antivirals for Chronic Hepatitis C Genotypes 5 and 6 (BioMed research international, 2019) Systematic review Cost-effectiveness of sofosbuvir- ledipasvir for Hepatitis C treatment: a systematic review (European journal of clinical pharmacology, 2026) Clinical trial publication Feasibility, safety, efficacy and potential scaling-up of sofosbuvir-based HCV treatment in Central and West Africa: (TAC ANRS 12311 trial) (Scientific reports, 2024) Clinical trial publication Statins Increase the Bioavailability of Fixed-Dose Combination of Sofosbuvir/Ledipasvir by Inhibition of P-glycoprotein (Drug research, 2022) Clinical trial publication Sustainable and equivalent improvements in symptoms and functional well-being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis C infection: Findings from the randomized PRIORITIZE trial (Journal of viral hepatitis, 2022) Clinical trial publication Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: a randomized controlled trial (Journal of medicine and life, 2022) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
OMBITASVIR	Small molecule	Approved	Strong	100	8 trials 5 Cochrane 11 Meta-analysis 77 Trial pubs 35 RCT View evidence Registry trials NCT01833533 — A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection (COMPLETED) PHASE3 NCT02786537 — Study of Oral Treatments for Hepatitis C (COMPLETED) PHASE4 NCT02615145 — Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C) (COMPLETED) NCT03341988 — Evaluation of Treatment of Chronic HCV Patients in Chronic Kidney Disease Versus End Stage Renal Disease Patients (COMPLETED) PHASE1 NCT02618928 — The Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in France (COMPLETED) NCT01995071 — A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV) (COMPLETED) PHASE2 NCT03050905 — Proof of Concept Study To Evaluate the Efficacy and Justification Of OBV/PTV/r and DSV In Adults With Chronic Hepatitis C Virus Genotype 2K/1B (COMPLETED) PHASE4 NCT03053180 — Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir (r) - Ombitasvir, + Dasabuvir Without Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis in the Russian Federation (COMPLETED) Published literature Cochrane review The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis (Frontiers in public health, 2023) Cochrane review Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review (Frontiers in public health, 2022) Cochrane review Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis (Journal of hepatology, 2019) Cochrane review Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis (Liver international : official journal of the International Association for the Study of the Liver, 2017) Cochrane review Safety of interferon-free therapies for chronic hepatitis C: a network meta-analysis (Journal of clinical pharmacy and therapeutics, 2016) Meta-analysis Efficacy and safety of direct acting antiviral regimens for hepatitis C virus and human immunodeficiency virus co-infection: systematic review and network meta-analysis (Journal of gastroenterology and hepatology, 2020) Meta-analysis Sustained Virological Response in Special Populations with Chronic Hepatitis C Using Interferon-Free Treatments: A Systematic Review and Meta-analysis of Observational Cohort Studies (Clinical drug investigation, 2018) Meta-analysis Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin for Treatment of Hepatitis C Virus Genotype 1: A Systematic Review and Meta-analysis (Clinical drug investigation, 2017) Clinical trial publication A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study (Hepatology (Baltimore, Md.), 2021) Clinical trial publication Impact of IL28B gene polymorphism on efficacy and safety of direct acting antivirals in hepatitis C Egyptian patients (International journal of clinical pharmacy, 2020) Clinical trial publication Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus-HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune Activation (The Journal of infectious diseases, 2020) Clinical trial publication High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience (Archives of virology, 2020) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
PARITAPREVIR	Small molecule	Approved	Strong	100	8 trials 5 Cochrane 11 Meta-analysis 70 Trial pubs 31 RCT View evidence Registry trials NCT01833533 — A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection (COMPLETED) PHASE3 NCT02786537 — Study of Oral Treatments for Hepatitis C (COMPLETED) PHASE4 NCT02615145 — Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C) (COMPLETED) NCT03341988 — Evaluation of Treatment of Chronic HCV Patients in Chronic Kidney Disease Versus End Stage Renal Disease Patients (COMPLETED) PHASE1 NCT02618928 — The Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in France (COMPLETED) NCT01995071 — A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV) (COMPLETED) PHASE2 NCT02068222 — A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection (COMPLETED) PHASE2 NCT03050905 — Proof of Concept Study To Evaluate the Efficacy and Justification Of OBV/PTV/r and DSV In Adults With Chronic Hepatitis C Virus Genotype 2K/1B (COMPLETED) PHASE4 Published literature Cochrane review The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis (Frontiers in public health, 2023) Cochrane review Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review (Frontiers in public health, 2022) Cochrane review Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis (Journal of hepatology, 2019) Cochrane review Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis (Liver international : official journal of the International Association for the Study of the Liver, 2017) Cochrane review Safety of interferon-free therapies for chronic hepatitis C: a network meta-analysis (Journal of clinical pharmacy and therapeutics, 2016) Meta-analysis Efficacy and safety of direct acting antiviral regimens for hepatitis C virus and human immunodeficiency virus co-infection: systematic review and network meta-analysis (Journal of gastroenterology and hepatology, 2020) Meta-analysis Direct-acting antiviral agents for liver transplant recipients with recurrent genotype 1 hepatitis C virus infection: Systematic review and meta-analysis (Transplant infectious disease : an official journal of the Transplantation Society, 2019) Meta-analysis Sustained Virological Response in Special Populations with Chronic Hepatitis C Using Interferon-Free Treatments: A Systematic Review and Meta-analysis of Observational Cohort Studies (Clinical drug investigation, 2018) Clinical trial publication A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study (Hepatology (Baltimore, Md.), 2021) Clinical trial publication Impact of IL28B gene polymorphism on efficacy and safety of direct acting antivirals in hepatitis C Egyptian patients (International journal of clinical pharmacy, 2020) Clinical trial publication Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus-HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune Activation (The Journal of infectious diseases, 2020) Clinical trial publication High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience (Archives of virology, 2020) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
RITONAVIR	Small molecule	Approved	Strong	100	8 trials 6 Cochrane 12 Meta-analysis 128 Trial pubs 60 RCT View evidence Registry trials NCT01220947 — A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection (COMPLETED) PHASE2 NCT01833533 — A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection (COMPLETED) PHASE3 NCT01323257 — TMC435-TiDP16-C115 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Erythromycin and Between TMC435 and Darunavir/Ritonavir (DRV/r) (COMPLETED) PHASE1 NCT02786537 — Study of Oral Treatments for Hepatitis C (COMPLETED) PHASE4 NCT00437476 — Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Antiretroviral (ARV) Naive Patients Starting Treatment With Anti-HCV Therapy (UNKNOWN) PHASE3 NCT02615145 — Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C) (COMPLETED) NCT03341988 — Evaluation of Treatment of Chronic HCV Patients in Chronic Kidney Disease Versus End Stage Renal Disease Patients (COMPLETED) PHASE1 NCT00023218 — Effect of a Change in HIV Therapy on Liver Steatosis, Inflammation, and Fibrosis (WITHDRAWN) NA Published literature Cochrane review The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis (Frontiers in public health, 2023) Cochrane review Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review (Frontiers in public health, 2022) Cochrane review Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis (Journal of hepatology, 2019) Cochrane review Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis (Liver international : official journal of the International Association for the Study of the Liver, 2017) Cochrane review Safety of interferon-free therapies for chronic hepatitis C: a network meta-analysis (Journal of clinical pharmacy and therapeutics, 2016) Meta-analysis Efficacy and safety of direct acting antiviral regimens for hepatitis C virus and human immunodeficiency virus co-infection: systematic review and network meta-analysis (Journal of gastroenterology and hepatology, 2020) Meta-analysis Direct-acting antiviral agents for liver transplant recipients with recurrent genotype 1 hepatitis C virus infection: Systematic review and meta-analysis (Transplant infectious disease : an official journal of the Transplantation Society, 2019) Meta-analysis Sustained Virological Response in Special Populations with Chronic Hepatitis C Using Interferon-Free Treatments: A Systematic Review and Meta-analysis of Observational Cohort Studies (Clinical drug investigation, 2018) Clinical trial publication A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study (Hepatology (Baltimore, Md.), 2021) Clinical trial publication Impact of IL28B gene polymorphism on efficacy and safety of direct acting antivirals in hepatitis C Egyptian patients (International journal of clinical pharmacy, 2020) Clinical trial publication [Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C] (Terapevticheskii arkhiv, 2019) Clinical trial publication Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus-HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune Activation (The Journal of infectious diseases, 2020) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
SOFOSBUVIR	Small molecule	Approved	Strong	100	8 trials 28 Cochrane 60 Meta-analysis 327 Trial pubs 144 RCT View evidence Registry trials NCT03158857 — Hepatitis C Treatment Study in Myanmar (WITHDRAWN) NCT03057847 — Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection (COMPLETED) PHASE4 NCT02605304 — 12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF (TERMINATED) PHASE2 NCT02786537 — Study of Oral Treatments for Hepatitis C (COMPLETED) PHASE4 NCT04948801 — SOF/VEL±RBV: Efficacy and Safety in GT 3 and 6 HCV Patients (UNKNOWN) NCT01994486 — Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1 (COMPLETED) PHASE2 NCT03809533 — The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients (ACTIVE_NOT_RECRUITING) PHASE2 NCT03369327 — Sofosbuvir and Daclatasvir for Treating Hepatitis C in 200 Patients Co-infected With Human Immunodeficiency Virus (COMPLETED) PHASE3 Published literature Cochrane review Glecaprevir/Pibrentasvir Versus Sofosbuvir/Velpatasvir for Hepatitis C Virus Genotype 6: A Systematic Review and Meta-Analysis (Reviews in medical virology, 2025) Cochrane review Efficacy and safety of direct-acting antiviral regimen for patients with hepatitis C virus genotype 2: a systematic review and meta-analysis (BMC gastroenterology, 2024) Cochrane review The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis (Frontiers in public health, 2023) Cochrane review The impact of sofosbuvir/velpatasvir/voxilaprevir treatment on serum hyperglycemia in hepatitis C virus infections: a systematic review and meta-analysis (Annals of medicine, 2023) Cochrane review Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis (Medicine, 2022) Meta-analysis Efficacy and Safety of Velpatasvir Plus Sofosbuvir With or Without Ribavirin in Hepatitis C Patients With Decompensated Cirrhosis: A Systematic Review and Meta-Analysis (Journal of viral hepatitis, 2025) Meta-analysis Efficacy of 8-week daclatasvir-sofosbuvir regimen in chronic hepatitis C: a systematic review and meta-analysis (Virology journal, 2024) Meta-analysis Prevalence of Drug Resistance Associated Substitutions in Persons With Chronic Hepatitis C Infection and Virological Failure Following Initial or Re-treatment With Pan-genotypic Direct-Acting Antivirals: A Systematic Review and Meta-analysis (Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2024) Systematic review Cost-effectiveness of sofosbuvir- ledipasvir for Hepatitis C treatment: a systematic review (European journal of clinical pharmacology, 2026) Clinical trial publication A Multicenter, open-label, randomized, non-inferiority trial of 8 versus 12 weeks of sofosbuvir/ravidasvir treatment in non-cirrhotic patients with chronic hepatitis C virus infection (EASE trial) (International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2026) Clinical trial publication Sofosbuvir/Velpatasvir/Voxilaprevir Versus Sofosbuvir/Velpatasvir Plus Ribavirin in Patients With Hepatitis C Virus Genotype 3b and Compensated Cirrhosis: A Multicentre Randomized Controlled Trial (Journal of medical virology, 2025) Clinical trial publication Long-term changes in hepatic reserve and prognosis after direct-acting antiviral treatment in patients with hepatitis C virus-related decompensated cirrhosis: a five-year follow-up study of a Japanese phase 3 trial (Journal of gastroenterology, 2026) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
ALBINTERFERON ALFA-2B	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
ALISPORIVIR	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
AMANTADINE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
ASUNAPREVIR	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
BECLABUVIR	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
DANOPREVIR	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
DASABUVIR	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
EFAVIRENZ	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
ELBASVIR	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
ELTROMBOPAG	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
EMTRICITABINE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
EPOETIN ALFA	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
ERGOCALCIFEROL	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
FALDAPREVIR	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
INFLIXIMAB	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
INTERFERON ALFA	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
INTERFERON ALFA-2A	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
INTERFERON ALFA-2B	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
INTERFERON ALFACON-1	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
INTERFERON BETA-1A	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
LOPINAVIR	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
PEGINTERFERON ALFA-2A	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
PEGINTERFERON LAMBDA-1A	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
PRADIGASTAT	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
RILPIVIRINE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
RUZASVIR	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
SIMEPREVIR	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
VANIPREVIR	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
ALLANTOIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BEMNIFOSBUVIR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BOCEPREVIR	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
CEPEGINTERFERON ALFA-2B	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CHEMBL1255891	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL1456	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHOLECALCIFEROL	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
COBICISTAT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DACLATASVIR	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
DELEOBUVIR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ELVITEGRAVIR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
EMTRICITABINE, (+/-)-	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FURAPREVIR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
GLECAPREVIR	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
GRAZOPREVIR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
GRAZOPREVIR ANHYDROUS	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
NELITOLIMOD	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
NOVAFERON	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PEGINTERFERON ALFA-2B	Biologic	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
PIBRENTASVIR	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
RIBAVIRIN	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
ROPEGINTERFERON ALFA-2B	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SILYBIN A	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TARIBAVIRIN HYDROCHLORIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TELAPREVIR	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
TENOFOVIR ALAFENAMIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
THYMALFASIN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
YIMITASVIR	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
YIMITASVIR PHOSPHATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ATORVASTATIN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
BETAINE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
CYCLOSPORINE	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
FILIBUVIR	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
FLUVASTATIN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
MERICITABINE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
MIFEPRISTONE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
MIRAVIRSEN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
NESBUVIR	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
NITAZOXANIDE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
PIOGLITAZONE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
PREDNISONE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
RALTEGRAVIR	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
RAVIDASVIR	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ROSUVASTATIN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
SAMATASVIR	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
SETROBUVIR	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
SILIBININ	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
SOVAPREVIR	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
THALIDOMIDE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
UPRIFOSBUVIR	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
VELPATASVIR	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ABT-072	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ABT-384	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ADAFOSBUVIR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ADEFOVIR DIPIVOXIL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ADEMETIONINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AVATROMBOPAG	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BEMNIFOSBUVIR SULFATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BMS-986094	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CHEMBL1016	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1200574	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201482	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1569	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1617	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1908360	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL269732	Small molecule	Phase II	Emerging	60	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
CTS-1027	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EMRICASAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EZETIMIBE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GS-9256	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
INTERFERON GAMMA-1B	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ISATORIBINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ISATORIBINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LOMIBUVIR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LUTETIUM OXODOTREOTIDE LU-177	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MBL-HCV-1	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MERIMEPODIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MITOQUINONE CATION	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NIM811	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NIVOCASAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ODALASVIR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PEMBROLIZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PF-4136309	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PSI-352938	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RADALBUVIR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RAVIDASVIR HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RG-7795	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SCY 635	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TARIBAVIRIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TEGOBUVIR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TEMAVIRSEN SODIUM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TMC-647055	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TREMELIMUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
UT-231B	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VEDROPREVIR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VX-135	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
WARFARIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ABACAVIR	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
BAVITUXIMAB	Biologic	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
BUPRENORPHINE	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
CLEMIZOLE	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
HYDROXYCHLOROQUINE	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
INTERFERON	Biologic	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
NALOXONE	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
TENOFOVIR DISOPROXIL FUMARATE	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
VESATOLIMOD	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
VOXILAPREVIR	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
4'-AZIDOCYTIDINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ALDESLEUKIN	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
AZD-7295	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BALAPIRAVIR	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BILB-1941	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BMS-929075	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CHEMBL1162	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL1323	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL1422	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL1503	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL1508	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL1751	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL192	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL2108518	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL2108956	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL32	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL532	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL651	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL655	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL691	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL8	Small molecule	Phase I	Emerging	35	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
CHEMBL809	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CILUPREVIR	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CPG-52852	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DELDEPREVIR	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DOLUTEGRAVIR	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ELSULFAVIRINE SODIUM	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
EPIGALOCATECHIN GALLATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ERLOTINIB	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
FURAPROFEN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GS-6620	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
GSK-625433	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
INTERLEUKIN-7	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ITX-5061	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
JTK-853	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MK-2748	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MK-3281	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MK-6325	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MK-8876	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NAMODENOSON	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
NIVOLUMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ROCAKINOGENE SIFUPLASMID	Gene therapy	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ST. JOHN'S WORT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TILSOTOLIMOD	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TILSOTOLIMOD SODIUM	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TIPRANAVIR	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
TMC-649128	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VCH-759	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
XTL-6865	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
COLCHICINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
DEXAMETHASONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
HISTAMINE DIHYDROCHLORIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
HYDROCORTISONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
LAMIVUDINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
METHYLPREDNISOLONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
METHYLPREDNISOLONE ACETATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
POLYETHYLENE GLYCOL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
POLYETHYLENE GLYCOL 3350	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
POLYETHYLENE GLYCOL 4000	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PREDNISOLONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
RIMANTADINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
RITUXIMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SILYMARIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TACROLIMUS	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TAURURSODIOL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TENOFOVIR	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TRIAMCINOLONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TRIAMCINOLONE ACETONIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
URSODIOL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
ACETAZOLAMIDE Repurposing via ACE	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ACETYLCHOLINE Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
AMPHETAMINE Repurposing via ACE	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ANGIOTENSIN II Repurposing via AGTR1	Small molecule	Approved	Strong	95	1 trials 2 Trial pubs View evidence Registry trials NCT03944447 — Outcomes Mandate National Integration With Cannabis as Medicine (UNKNOWN) PHASE2 Published literature Clinical trial publication Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C (American journal of physiology. Gastrointestinal and liver physiology, 2009) Clinical trial publication Therapeutic effect of ARBs on insulin resistance and liver injury in patients with NAFLD and chronic hepatitis C: a pilot study (International journal of molecular medicine, 2008) CT.gov search · Cochrane · PubMed	DGIdb	—
ANGIOTENSIN II ACETATE Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ARGIPRESSIN Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
ASCORBIC ACID Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	—
ASPIRIN Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
ATORVASTATIN Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	—
ATORVASTATIN CALCIUM TRIHYDRATE Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	—
AZACITIDINE Repurposing via AFP	Small molecule	Approved	Strong	95	—	DGIdb	—
AZILSARTAN KAMEDOXOMIL Repurposing via AGTR1	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
AZILSARTAN MEDOXOMIL Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	—
BENAZEPRIL Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	—
BENAZEPRIL HYDROCHLORIDE Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BENAZEPRILAT Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
BETAINE Repurposing via BHMT2	Small molecule	Approved	Strong	95	3 trials 1 Trial pubs 1 RCT View evidence Registry trials NCT00571714 — Pilot Comparison of Standard Antiviral Therapy With and Without 12 Weeks of Betaine in Genotype 1 Naive Patients (WITHDRAWN) NA NCT00310336 — Chronic Hepatitis C Non-Responder Study With AdoMet and Betaine (COMPLETED) PHASE2, PHASE3 NCT00882193 — Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers (TERMINATED) EARLY_PHASE1 Published literature Clinical trial publication S-adenosyl-methionine and betaine improve early virological response in chronic hepatitis C patients with previous nonresponse (PloS one, 2010) CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
BICALUTAMIDE Repurposing via ACE	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BLEOMYCIN Repurposing via AFP	Small molecule	Approved	Strong	95	—	DGIdb	—
BUMETANIDE Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
BUPROPION HYDROCHLORIDE Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
CANDESARTAN CILEXETIL Repurposing via AGTR1	Small molecule	Approved	Strong	95	2 trials View evidence Registry trials NCT03770936 — Effect of Some Drugs on Liver Fibrosis (RECRUITING) PHASE3 NCT00930995 — Angiotensin Receptor Blockade as an Anti-Fibrotic Intervention in Patients With Chronic Hepatitis C (WITHDRAWN) PHASE2 CT.gov search · Cochrane · PubMed	DGIdb	—
CANDOXATRIL Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPTOPRIL Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	—
CARBACHOL Repurposing via ACE	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CILAZAPRIL Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
CIPROFLOXACIN Repurposing via ACE	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
CLOMIPRAMINE Repurposing via ACE	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CYCLOSPORINE Repurposing via AGTR1	Small molecule	Approved	Strong	95	8 trials 2 Cochrane 4 Meta-analysis 43 Trial pubs 16 RCT View evidence Registry trials NCT01467505 — An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients (TERMINATED) PHASE2 NCT03665766 — Effect of Cyclosporine A Versus Tacrolimus on Response to Antiviral Therapy After Hepatitis C Genotype -4 Recurrence Post Liver Transplantation (COMPLETED) NCT01479881 — A Study in Healthy Participants Investigating the Effect of TMC435 on the Pharmacokinetics of Immunosuppressants Cyclosporine and Tacrolimus (COMPLETED) PHASE1 NCT00983060 — Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients (COMPLETED) PHASE2 NCT00284921 — MYPROMS-ES02: Safety and Efficacy of Basiliximab, Cyclosporine Microemulsion and Enteric-coated Mycophenolate Sodium (EC-MPS) Versus EC-MPS and Steroid Therapy in Kidney Transplant Recipients Who Are Hepatitis C Positive (TERMINATED) PHASE3 NCT00375895 — Switch From Tacrolimus to Cyclosporin in the Treatment of Recurrent Hepatitis C After Liver Transplantation (TERMINATED) PHASE3 NCT04113915 — Viral Hepatitis B and C Infection in Patients With Idiopathic Thrombocytopenic Purpura Treated With Triple Therapy (UNKNOWN) NCT00668369 — Effect of Immunosuppression Drug Weaning on Hepatitis C Virus (HCV)-Induced Liver Damage After Liver Transplantation (COMPLETED) PHASE2 Published literature Cochrane review Efficacy of immunosuppression monotherapy after liver transplantation: a meta-analysis (World journal of gastroenterology, 2014) Cochrane review Tacrolimus-based versus cyclosporine-based immunosuppression in hepatitis C virus-infected patients after liver transplantation: a meta-analysis and systematic review (PloS one, 2014) Meta-analysis Efficacy of antiviral therapy for hepatitis C after liver transplantation with cyclosporine and tacrolimus: a systematic review and meta-analysis (Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2013) Meta-analysis Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis (Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2007) Clinical trial publication Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients (Journal of hepatology, 2018) Clinical trial publication Pharmacokinetic Interaction between Faldaprevir and Cyclosporine or Tacrolimus in Healthy Volunteers: A Prospective, Open-Label, Fixed-Sequence, Crossover Study (Basic & clinical pharmacology & toxicology, 2018) Clinical trial publication Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study (Transplant infectious disease : an official journal of the Transplantation Society, 2017) Clinical trial publication Twice-Daily Telaprevir for Posttransplant Genotype 1 Hepatitis C Virus: A Prospective Safety, Efficacy, and Pharmacokinetics Study (Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2018) Clinical trial publication Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection (Therapeutic drug monitoring, 2016) Randomized controlled trial Sustained virological response to antiviral therapy in a randomized trial of cyclosporine versus tacrolimus in liver transplant patients with recurrent hepatitis C infection (Annals of transplantation, 2015) Randomized controlled trial REFINE: a randomized trial comparing cyclosporine A and tacrolimus on fibrosis after liver transplantation for hepatitis C (American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2014) Randomized controlled trial Hepatitis C virus viral kinetics during α-2a or α-2b pegylated interferon plus ribavirin therapy in liver transplant recipients with different immunosuppression regimes (Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2012) CT.gov search · Cochrane · PubMed	DGIdb	—
DACTINOMYCIN Repurposing via AFP	Small molecule	Approved	Strong	95	—	DGIdb	—
DESERPIDINE Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
DEXAMETHASONE Repurposing via AGTR1	Small molecule	Approved	Strong	95	1 trials View evidence Registry trials NCT04113915 — Viral Hepatitis B and C Infection in Patients With Idiopathic Thrombocytopenic Purpura Treated With Triple Therapy (UNKNOWN) CT.gov search · Cochrane · PubMed	DGIdb	—
DIAZEPAM Repurposing via ACE	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing via ACE	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing via ACE	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DISULFIRAM Repurposing via AGTR1	Small molecule	Approved	Strong	95	1 Cochrane 1 Trial pubs View evidence Published literature Cochrane review Systematic review of the pharmacological treatment of alcohol use disorders in individuals infected with hepatitis C (Addiction science & clinical practice, 2015) Clinical trial publication Disulfiram therapy in patients with hepatitis C: a 12-month, controlled, follow-up study (Journal of studies on alcohol, 2004) CT.gov search · Cochrane · PubMed	DGIdb	—
DOXORUBICIN HYDROCHLORIDE Repurposing via AFP	Small molecule	Approved	Strong	95	—	DGIdb	—
ENALAPRIL MALEATE Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
ENALAPRILAT Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ENALAPRILAT ANHYDROUS Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
EPIRUBICIN Repurposing via ACE	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
EPOETIN ALFA Repurposing via AFP	Small molecule	Approved	Strong	95	—	DGIdb	—
EPROSARTAN Repurposing via AGTR1	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
EPROSARTAN MESYLATE Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ETHOXZOLAMIDE Repurposing via ACE	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ETOPOSIDE Repurposing via AFP	Small molecule	Approved	Strong	95	—	DGIdb	—
FLUMAZENIL Repurposing via ACE	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
FLUOXETINE HYDROCHLORIDE Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
FOLIC ACID Repurposing via AFP	Small molecule	Approved	Strong	95	—	DGIdb	—
FOSINOPRIL Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
FOSINOPRIL SODIUM Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
FUROSEMIDE Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
GENISTEIN Repurposing via AGTR1	Small molecule	Approved	Strong	95	1 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
HYDROCHLOROTHIAZIDE Repurposing via AGTR1	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
HYDROGEN PEROXIDE Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	—
IMIDAPRIL Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
IMIPRAMINE Repurposing via ACE	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDAPAMIDE Repurposing via ACE	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDOMETHACIN Repurposing via AGTR1	Small molecule	Approved	Strong	95	1 Trial pubs View evidence Published literature Clinical trial publication [Treatment of chronic virus hepatitis with acetylsalicylic acid] (Schweizerische medizinische Wochenschrift, 1995) CT.gov search · Cochrane · PubMed	DGIdb	—
INDOMETHACIN Repurposing via ACE	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
IRBESARTAN Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	—
IRBESARTAN HYDROCHLORIDE Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ISOSORBIDE DINITRATE Repurposing via ACE	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
LEVODOPA Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	—
LISINOPRIL Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
LISINOPRIL ANHYDROUS Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
LOSARTAN POTASSIUM Repurposing via AGTR1	Small molecule	Approved	Strong	95	1 trials View evidence Registry trials NCT00298714 — Effects of Losartan on Hepatic Fibrogenesis in Chronic Hepatitis C (COMPLETED) PHASE4 CT.gov search · Cochrane · PubMed	DGIdb	—
MAFENIDE Repurposing via ACE	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MALATHION Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
MASOPROCOL Repurposing via AFP	Small molecule	Approved	Strong	95	—	DGIdb	—
MECAMYLAMINE Repurposing via ACE	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MESALAMINE Repurposing via CASP1	Small molecule	Approved	Strong	95	—	DGIdb	—
METHAZOLAMIDE Repurposing via ACE	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHOTREXATE Repurposing via AFP	Small molecule	Approved	Strong	95	—	DGIdb	—
METHOXSALEN Repurposing via ACE	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METOPROLOL Repurposing via ACE	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MIANSERIN Repurposing via ACE	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MIFEPRISTONE Repurposing via AFP	Small molecule	Approved	Strong	95	—	DGIdb	—
MOEXIPRIL Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
MOEXIPRIL HYDROCHLORIDE Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
NALIDIXIC ACID Repurposing via ACE	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NICOTINE Repurposing via ACE	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NICOTINE POLACRILEX Repurposing via AFP	Small molecule	Approved	Strong	95	—	DGIdb	—
NITROPRUSSIDE Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
NORFLOXACIN Repurposing via ACE	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
OFLOXACIN Repurposing via ACE	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
OLMESARTAN MEDOXOMIL Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	—
PEGINTERFERON ALFA-2B Repurposing via CASP1	Small molecule	Approved	Strong	95	—	DGIdb	—
PERINDOPRIL Repurposing via AGTR1	Small molecule	Approved	Strong	95	1 Trial pubs 1 RCT View evidence Published literature Clinical trial publication Interferon augments the anti-fibrotic activity of an angiotensin-converting enzyme inhibitor in patients with refractory chronic hepatitis C (World journal of gastroenterology, 2006) CT.gov search · Cochrane · PubMed	DGIdb	—
PERINDOPRIL ARGININE Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PERINDOPRIL ERBUMINE Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
PERINDOPRILAT Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
PHENYTOIN Repurposing via ACE	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
POLYETHYLENE GLYCOL 4000 Repurposing via AFP	Small molecule	Approved	Strong	95	—	DGIdb	—
PRAVASTATIN SODIUM Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
PRAZOSIN Repurposing via ACE	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
QUINAPRIL Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
QUINAPRIL HYDROCHLORIDE Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
QUINAPRILAT Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
RAMIPRIL Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
RAMIPRILAT Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
RESCINNAMINE Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
RIBAVIRIN Repurposing via CASP1	Small molecule	Approved	Strong	95	—	DGIdb	—
RUTIN Repurposing via AFP	Small molecule	Approved	Strong	95	—	DGIdb	—
SARALASIN ACETATE Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
SILDENAFIL Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
SIROLIMUS Repurposing via ACE	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
SODIUM CHLORIDE Repurposing via AGTR1	Small molecule	Approved	Strong	95	8 trials View evidence Registry trials NCT00800007 — Study of Safety and Tolerability of Multiple Intravenous Doses of ANZ-521 in Adults With Chronic Hepatitis C Virus (TERMINATED) PHASE1, PHASE2 NCT00990938 — Study of Combination Treatment With IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 Patients (COMPLETED) PHASE1 NCT01518933 — Effect of LEGALON SIL on Hepatitis C Virus Recurrence in Stable Liver Transplanted Patients (TERMINATED) PHASE2 NCT01459419 — Oral Administration of Anti-CD3 Monoclonal Antibody in Non-responder Genotype-I Chronic Hepatitis C Subjects (UNKNOWN) PHASE2 NCT07237282 — A Phase 1 Clinical Trial of Adjuvanted Protein-based HCV Vaccine Candidates (HCV Vaccine Trial) (NOT_YET_RECRUITING) PHASE1 NCT02340962 — Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection (COMPLETED) PHASE2 NCT00500747 — Chiron Corp HCV E1/E2 Vaccine (COMPLETED) PHASE1 NCT00728936 — Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients (COMPLETED) PHASE1 CT.gov search · Cochrane · PubMed	DGIdb	—
SPARSENTAN Repurposing via AGTR1	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
SPIRAPRIL Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
SPIRAPRIL HYDROCHLORIDE Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
SULBACTAM Repurposing via ACE	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TACROLIMUS ANHYDROUS Repurposing via ACE	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
TAZOBACTAM Repurposing via ACE	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TELMISARTAN Repurposing via AGTR1	Small molecule	Approved	Strong	95	1 Trial pubs View evidence Published literature Clinical trial publication Therapeutic effect of ARBs on insulin resistance and liver injury in patients with NAFLD and chronic hepatitis C: a pilot study (International journal of molecular medicine, 2008) CT.gov search · Cochrane · PubMed	DGIdb	—
TORSEMIDE Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
TRANDOLAPRIL Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
TRANDOLAPRILAT Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
TROGLITAZONE Repurposing via ACE	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
VALSARTAN Repurposing via AGTR1	Small molecule	Approved	Strong	95	1 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
VINCRISTINE Repurposing via AFP	Small molecule	Approved	Strong	95	—	DGIdb	—
VORINOSTAT Repurposing via ACE	Small molecule	Approved	Strong	95	—	DGIdb	—
DARAPLADIB Repurposing via ACE	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
FENRETINIDE Repurposing via ACE	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
BELNACASAN Repurposing via CASP1	Small molecule	Phase II	Emerging	50	—	DGIdb	ChEMBL Open Targets
CHEMBL:CHEMBL265439 Repurposing via CASP2	Small molecule	Phase II	Emerging	50	—	DGIdb	ChEMBL Open Targets
CHEMBL:CHEMBL34833 Repurposing via CASP2	Small molecule	Phase II	Emerging	50	—	DGIdb	ChEMBL Open Targets
CHEMBL:CHEMBL415893 Repurposing via CASP1	Small molecule	Phase II	Emerging	50	—	DGIdb	ChEMBL Open Targets
EMRICASAN Repurposing via CASP12	Small molecule	Phase II	Emerging	50	—	DGIdb	—
GRASSYSTATIN A Repurposing via CASP14	Small molecule	Phase II	Emerging	50	—	DGIdb	—
PRALNACASAN Repurposing via CASP1	Small molecule	Phase II	Emerging	50	—	DGIdb	—
TASOSARTAN Repurposing via AGTR1	Small molecule	Phase II	Emerging	50	—	DGIdb	—
VERMISTATIN Repurposing via CASP1	Small molecule	Phase II	Emerging	50	—	DGIdb	ChEMBL Open Targets
Z-VDVAD-FMK Repurposing via CASP2	Small molecule	Phase II	Emerging	50	—	DGIdb	—
ALPRENOLOL Repurposing via ACE	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
AMIFLOXACIN Repurposing via ACE	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
BROLAMFETAMINE Repurposing via ACE	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
CARZENIDE Repurposing via ACE	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIFLOXACIN Repurposing via ACE	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIMECAMINE Repurposing via ACE	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ELLAGIC ACID Repurposing via ACE	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ENISOPROST Repurposing via ACE	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FENCAMFAMIN Repurposing via ACE	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FLEROXACIN Repurposing via ACE	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
IDOXIFENE Repurposing via ACE	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
LYSERGIDE Repurposing via ACE	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
MERAFLOXACIN Repurposing via ACE	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
TENAMFETAMINE Repurposing via ACE	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ZIDAPAMIDE Repurposing via ACE	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets

Natural Products

105 natural products with the same evidence schema as repurposed drugs — registry trials, PubMed literature, and reference links (pipeline-ranked). Only agents with direct clinical evidence are shown by default.

Reference lookups: Examine.com

Show agents without direct trial evidence

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
Folate Natural product Human Study Folic acid may have a therapeutic effect in treating viral hepatitis. Human Study Viusid, a nutritional supplement containing glucosamine, malic acid, li…	Nutraceutical	Approved	Emerging	19	3 trials View evidence Registry trials NCT03283176 — Hematologic Profile, Vit. B12 and Folic Acid in Cirrhotics Received Sofosbuvir and Daclatasvir With or Without Ribavirin (COMPLETED) NCT00755950 — Randomized Placebo-controlled Trial Evaluating the Safety and Efficacy of Silymarin Treatment in Patients With Acute Viral Hepatitis (TERMINATED) PHASE2, PHASE3 NCT02150291 — A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin. (UNKNOWN) PHASE4 CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	PubChem
Vitamin D3 Natural product Human Study High-dose vitamins E and C supplementation prevents ribavirin-induced h… Human Study Prevalence of Vitamin-D deficiency is related to severity of liver dama… Human Study Treatment with a milk thistle (silybin), vitamin E and phospholipid for…	Nutraceutical	Approved	Emerging	19	8 trials View evidence Registry trials NCT02120274 — Vitamin D and Vitamin B12 Supplementation With Pegylated Interferon-Alfa Plus Ribavirin for Treating Chronic Hepatitis C (TERMINATED) PHASE4 NCT01890772 — Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1 (WITHDRAWN) PHASE2, PHASE3 NCT02099604 — Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C (WITHDRAWN) PHASE3 NCT01439776 — Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients (COMPLETED) PHASE4 NCT02053519 — Can Vitamin D Supplementation Improve Hepatitis C Cure Rates (COMPLETED) PHASE3 NCT02788682 — Association of Vitamin D Binding Protein Polymorphisms With Response to HCV Therapy (COMPLETED) NCT02461979 — The Role of the Vitamin D Receptor Gene Polymorphisms in Hepatocarcinogenesis (UNKNOWN) NA NCT03820102 — Impact of Metabolic Changes and Vitamin D Status on Virological Response in Patients With HCV Infection Treated by DAAs (UNKNOWN) CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	PubChem
Silymarin Natural product Human Study A triple antioxidant approach to the treatment of hepatitis C may be su… Human Study A mixture of milk thistle and phosphatidylcholine (LiverPro) has therap… Human Study Camel milk had a regulatory effect on multiple parameters of inflammato…	Botanical	Phase III	Moderate	17	8 trials 2 Meta-analysis 11 RCT View evidence Registry trials NCT00680342 — Phase II Trial of Silymarin for Patients With Chronic Hepatitis C Who Have Failed Conventional Antiviral Treatment (COMPLETED) PHASE2 NCT01871662 — Randomized Study for the Assessment of Silibinin (Legalon® SIL) in the Treatment of naïve Genotype 4 Patients With Chronic Hepatitis C (WITHDRAWN) PHASE2, PHASE3 NCT00684268 — Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders (COMPLETED) PHASE2 NCT00389376 — Phase I Trial of Silymarin for Chronic Liver Diseases (COMPLETED) PHASE1 NCT01018615 — Safety, Metabolism, and Antioxidant Activity of Silymarin and Green Tea Extract in Patients With Chronic Hepatitis C (COMPLETED) PHASE1 NCT00755950 — Randomized Placebo-controlled Trial Evaluating the Safety and Efficacy of Silymarin Treatment in Patients With Acute Viral Hepatitis (TERMINATED) PHASE2, PHASE3 NCT00246363 — A Clinical Research Study Designed To Determine If Treatment of Hepatitis C With Milk Thistle is More Effective Than No Treatment In Patients Infected With Both HIV And Hepatitis C (COMPLETED) PHASE1, PHASE2 NCT01292161 — Effects of Silybum Marianum on Treatment of Patients With Chronic Hepatitis C (COMPLETED) PHASE2 CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Black Seed Oil Natural product Human Study Enhanced efficacy of direct-acting antivirals in hepatitis C patients b… Review Anti-infective properties of the golden spice curcumin.	Botanical	Preclinical	Moderate	17	No indexed hits View evidence CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Silymarin Natural product Human Study A mixture of milk thistle and phosphatidylcholine (LiverPro) has therap… Human Study Camel milk had a regulatory effect on multiple parameters of inflammato… Human Study Silibinin, a compound found within milk thistle, is well tolerated and…	Botanical	Phase III	Emerging	16	8 trials 2 Meta-analysis 11 RCT View evidence Registry trials NCT00680342 — Phase II Trial of Silymarin for Patients With Chronic Hepatitis C Who Have Failed Conventional Antiviral Treatment (COMPLETED) PHASE2 NCT01871662 — Randomized Study for the Assessment of Silibinin (Legalon® SIL) in the Treatment of naïve Genotype 4 Patients With Chronic Hepatitis C (WITHDRAWN) PHASE2, PHASE3 NCT00684268 — Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders (COMPLETED) PHASE2 NCT00389376 — Phase I Trial of Silymarin for Chronic Liver Diseases (COMPLETED) PHASE1 NCT01018615 — Safety, Metabolism, and Antioxidant Activity of Silymarin and Green Tea Extract in Patients With Chronic Hepatitis C (COMPLETED) PHASE1 NCT00755950 — Randomized Placebo-controlled Trial Evaluating the Safety and Efficacy of Silymarin Treatment in Patients With Acute Viral Hepatitis (TERMINATED) PHASE2, PHASE3 NCT00246363 — A Clinical Research Study Designed To Determine If Treatment of Hepatitis C With Milk Thistle is More Effective Than No Treatment In Patients Infected With Both HIV And Hepatitis C (COMPLETED) PHASE1, PHASE2 NCT01292161 — Effects of Silybum Marianum on Treatment of Patients With Chronic Hepatitis C (COMPLETED) PHASE2 CT.gov search · Cochrane · PubMed	ClinicalTrials.gov, Examine.com	PubChem Examine.com
Spirulina Natural product Meta-analysis Antiviral potential of spirulina in individuals with human immunodefici…	Nutraceutical	Phase II	Emerging	16	3 trials 1 Meta-analysis 2 Trial pubs 2 RCT View evidence Registry trials NCT02744547 — Effect of Spirulina on Serum Hyaluronic Acid in Beta Thalassemic Children With Hepatitis C (COMPLETED) NA NCT02744105 — Effect of Spirulina on Liver Fibrosis by Transient Elastography in Beta Thalassemic Children With Hepatitis C (COMPLETED) NA NCT02744560 — Effect of Spirulina on Liver Iron Concentration in Beta Thalassemic Children With Hepatitis C (COMPLETED) NA Published literature Meta-analysis Antiviral potential of spirulina in individuals with human immunodeficiency virus or Hepatis C virus infections: A systematic review and meta-analysis (Clinical nutrition ESPEN, 2024) CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	—
Omega-3 Fatty Acids Natural product Clinical trial publication Omega-3 fatty acids in the prevention of interferon-alpha-induced depre… Clinical trial publication Omega-3 fatty acids and/or fluvastatin in hepatitis C prior non-respond… Human Study Omega-3 fatty acids reduce fibrogenesis and increase responsiveness to…	Nutraceutical	Phase II	Emerging	16	2 trials 2 Trial pubs View evidence Registry trials NCT00408304 — Prevention of Depression With Omega-3 Fatty Acids in Chronic Carriers of Hepatitis C Treated With Interferon Alpha. (UNKNOWN) PHASE2 NCT00547716 — Use of Omega-3 Fatty Acids (Fish Oil) in Patients With Chronic Hepatitis C Infection (WITHDRAWN) NA Published literature Clinical trial publication Omega-3 fatty acids in the prevention of interferon-alpha-induced depression: results from a randomized, controlled trial (Biological psychiatry, 2014) Clinical trial publication Omega-3 fatty acids and/or fluvastatin in hepatitis C prior non-responders to combination antiviral therapy - a pilot randomised clinical trial (Liver international : official journal of the International Association for the Study of the Liver, 2014) CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	PubChem
Quercetin Natural product In Vitro Study Quercetin attenuates hepatitis C virus production.	Food compound	Phase I	Emerging	13	2 trials View evidence Registry trials NCT01438320 — Q-Trial in Patients With Hepatitis C (COMPLETED) PHASE1 NCT07487623 — Evaluation of the Hepatoprotective Effects of a Nutritional Supplement in Patients With Liver Disease Secondary to Chronic Hepatitis C Virus Infection (RESQUETI Study). (RECRUITING) NA CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	PubChem
Resveratrol Natural product Cochrane review A Systematic Review of the Impact of Resveratrol on Viral Hepatitis and… Clinical trial publication Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α… Meta Analysis Cesarean delivery does not decrease perinatal hepatitis C transmission…	Food compound	Phase I	Emerging	10	1 trials 1 Cochrane 1 Trial pubs View evidence Registry trials NCT07487623 — Evaluation of the Hepatoprotective Effects of a Nutritional Supplement in Patients With Liver Disease Secondary to Chronic Hepatitis C Virus Infection (RESQUETI Study). (RECRUITING) NA Published literature Cochrane review A Systematic Review of the Impact of Resveratrol on Viral Hepatitis and Chronic Viral Hepatitis-related Hepatocellular Carcinoma (Current molecular medicine, 2025) Clinical trial publication Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance (Nutrients, 2017) CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	PubChem
Tudca Natural product Targeting ER stress/PKA/GSK-3β/β-catenin pathway as a potential novel s… A controlled randomised trial of t-UDCA as adjuvant to interferon for t…	Nutraceutical	Preclinical	Moderate	10	1 pubs View evidence CT.gov search · Cochrane · PubMed	Examine.com	Examine.com
Vitamin D3 Natural product Human Study Prevalence of Vitamin-D deficiency is related to severity of liver dama… Human Study A multi antioxidative treatment in chronic hepatitis C virus patients i… Human Study Enhanced efficacy of direct-acting antivirals in hepatitis C patients b…	Nutraceutical	Approved	Emerging	10	8 trials View evidence Registry trials NCT02120274 — Vitamin D and Vitamin B12 Supplementation With Pegylated Interferon-Alfa Plus Ribavirin for Treating Chronic Hepatitis C (TERMINATED) PHASE4 NCT01890772 — Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1 (WITHDRAWN) PHASE2, PHASE3 NCT02099604 — Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C (WITHDRAWN) PHASE3 NCT01439776 — Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients (COMPLETED) PHASE4 NCT02053519 — Can Vitamin D Supplementation Improve Hepatitis C Cure Rates (COMPLETED) PHASE3 NCT02788682 — Association of Vitamin D Binding Protein Polymorphisms With Response to HCV Therapy (COMPLETED) NCT02461979 — The Role of the Vitamin D Receptor Gene Polymorphisms in Hepatocarcinogenesis (UNKNOWN) NA NCT03820102 — Impact of Metabolic Changes and Vitamin D Status on Virological Response in Patients With HCV Infection Treated by DAAs (UNKNOWN) CT.gov search · Cochrane · PubMed		PubChem
Vitamin C Natural product Randomized controlled trial Zinc supplementation prevents the increase of transaminase in chronic h… Randomized controlled trial The effect of antioxidant supplementation on hepatitis C viral load, tr… Randomized controlled trial Vitamin E and C supplementation prevents decrease of eicosapentaenoic a…	Nutraceutical	Approved	Emerging	10	8 trials 3 RCT View evidence Registry trials NCT02120274 — Vitamin D and Vitamin B12 Supplementation With Pegylated Interferon-Alfa Plus Ribavirin for Treating Chronic Hepatitis C (TERMINATED) PHASE4 NCT01890772 — Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1 (WITHDRAWN) PHASE2, PHASE3 NCT00165633 — A Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular Carcinoma (TERMINATED) PHASE2, PHASE3 NCT02099604 — Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C (WITHDRAWN) PHASE3 NCT01439776 — Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients (COMPLETED) PHASE4 NCT02053519 — Can Vitamin D Supplementation Improve Hepatitis C Cure Rates (COMPLETED) PHASE3 NCT02788682 — Association of Vitamin D Binding Protein Polymorphisms With Response to HCV Therapy (COMPLETED) NCT02461979 — The Role of the Vitamin D Receptor Gene Polymorphisms in Hepatocarcinogenesis (UNKNOWN) NA Published literature Randomized controlled trial Zinc supplementation prevents the increase of transaminase in chronic hepatitis C patients during combination therapy with pegylated interferon alpha-2b and ribavirin (Journal of nutritional science and vitaminology, 2007) Randomized controlled trial The effect of antioxidant supplementation on hepatitis C viral load, transaminases and oxidative status: a randomized trial among chronic hepatitis C virus-infected patients (European journal of gastroenterology & hepatology, 2006) Randomized controlled trial Vitamin E and C supplementation prevents decrease of eicosapentaenoic acid in mononuclear cells in chronic hepatitis C patients during combination therapy of interferon alpha-2b and ribavirin (Nutrition (Burbank, Los Angeles County, Calif.), 2006) CT.gov search · Cochrane · PubMed		PubChem
Vitamin E Natural product Clinical trial publication Silybin supplementation during HCV therapy with pegylated interferon-α… Clinical trial publication Beneficial effect of refined red palm oil on lipid peroxidation and mon… Clinical trial publication Effects of vitamin E on chronic hepatitis C genotype 3: a randomized, d…	Nutraceutical	Phase III	Emerging	10	4 trials 14 Trial pubs View evidence Registry trials NCT00119119 — Efficacy and Safety of Pentoxyphilline and Tocopherol on the Fibrosis in Patients With Chronic Hepatitis C (TERMINATED) PHASE3 NCT00983164 — Blood Antioxidant Status in Chronic Hepatitis C Patients Before and After Antioxidant Supplementation: a Randomized Clinical Trial (COMPLETED) NA NCT04271865 — Dates a Food Treasure in Alleviating Anemia (COMPLETED) NA NCT01935817 — Silybin - Vitamin E- Phospholipids Complex Reduces Liver Fibrosis in Patients With Chronic Hepatitis C Treated With Peg-IFN-a and RBV (COMPLETED) PHASE3 Published literature Clinical trial publication Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability (BMC psychiatry, 2016) Clinical trial publication Beneficial effect of refined red palm oil on lipid peroxidation and monocyte tissue factor in HCV-related liver disease: a randomized controlled study (Hepatobiliary & pancreatic diseases international : HBPD INT, 2016) Clinical trial publication Effects of vitamin E on chronic hepatitis C genotype 3: a randomized, double-blind, placebo-controlled study (Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2014) Clinical trial publication Antioxidant supplementation attenuates oxidative stress in chronic hepatitis C patients (Gastroenterologia y hepatologia, 2012) Clinical trial publication Zinc supplementation prevents the increase of transaminase in chronic hepatitis C patients during combination therapy with pegylated interferon alpha-2b and ribavirin (Journal of nutritional science and vitaminology, 2007) CT.gov search · Cochrane · PubMed		PubChem
Omega-3 Fatty Acids Natural product Clinical trial publication Omega-3 fatty acids in the prevention of interferon-alpha-induced depre… Clinical trial publication Omega-3 fatty acids and/or fluvastatin in hepatitis C prior non-respond… Human Study Eicosapentaenoic acid supplementation may be useful in therapy for chro…	Nutraceutical	Phase II	Emerging	10	2 trials 2 Trial pubs View evidence Registry trials NCT00408304 — Prevention of Depression With Omega-3 Fatty Acids in Chronic Carriers of Hepatitis C Treated With Interferon Alpha. (UNKNOWN) PHASE2 NCT00547716 — Use of Omega-3 Fatty Acids (Fish Oil) in Patients With Chronic Hepatitis C Infection (WITHDRAWN) NA Published literature Clinical trial publication Omega-3 fatty acids in the prevention of interferon-alpha-induced depression: results from a randomized, controlled trial (Biological psychiatry, 2014) Clinical trial publication Omega-3 fatty acids and/or fluvastatin in hepatitis C prior non-responders to combination antiviral therapy - a pilot randomised clinical trial (Liver international : official journal of the International Association for the Study of the Liver, 2014) CT.gov search · Cochrane · PubMed		PubChem
Zinc Natural product Cochrane review Role of zinc supplementation in the management of chronic liver disease… Clinical trial publication A randomized clinical study to evaluate the possible antifibrotic effec… Clinical trial publication Lack of Association Between Recent Cannabis Use and Advanced Liver Fibr…	Nutraceutical	Phase III	Emerging	10	2 trials 1 Cochrane 17 Trial pubs View evidence Registry trials NCT00983164 — Blood Antioxidant Status in Chronic Hepatitis C Patients Before and After Antioxidant Supplementation: a Randomized Clinical Trial (COMPLETED) NA NCT05465434 — Study to Evaluate the Possible Antifibrotic Effect of Zinc Sulphate in Chronic HCV Patient Receiving Direct Acting Anti-viral Therapy. (COMPLETED) PHASE3 Published literature Cochrane review Role of zinc supplementation in the management of chronic liver diseases: A systematic review and meta-analysis (Annals of hepatology, 2020) Clinical trial publication A randomized clinical study to evaluate the possible antifibrotic effect of zinc sulfate in chronic HCV patient receiving direct-acting anti-viral therapy (Inflammopharmacology, 2025) Clinical trial publication Lack of Association Between Recent Cannabis Use and Advanced Liver Fibrosis Among HIV-positive Heavy Drinkers (Current HIV research, 2021) Clinical trial publication Genome-Wide Association Study Identifies ZNF354C Variants Associated with Depression from Interferon-Based Therapy for Chronic Hepatitis C (PloS one, 2016) Clinical trial publication Serum Zinc and Haptoglobin in Noncirrhotic Azeri Patients with Chronic Active Hepatitis C: a Case-Control Study (Biological trace element research, 2015) Clinical trial publication Exacerbation of insulin resistance and hepatic steatosis deriving from zinc deficiency in patients with HCV-related chronic liver disease (Biological trace element research, 2015) CT.gov search · Cochrane · PubMed		PubChem
Folate Natural product Human Study Folic acid may have a therapeutic effect in treating viral hepatitis. Human Study Viusid, a nutritional supplement containing glucosamine, malic acid, li…	Nutraceutical	Approved	Emerging	10	3 trials View evidence Registry trials NCT03283176 — Hematologic Profile, Vit. B12 and Folic Acid in Cirrhotics Received Sofosbuvir and Daclatasvir With or Without Ribavirin (COMPLETED) NCT00755950 — Randomized Placebo-controlled Trial Evaluating the Safety and Efficacy of Silymarin Treatment in Patients With Acute Viral Hepatitis (TERMINATED) PHASE2, PHASE3 NCT02150291 — A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin. (UNKNOWN) PHASE4 CT.gov search · Cochrane · PubMed		PubChem
Black Seed Oil Natural product Human Study Enhanced efficacy of direct-acting antivirals in hepatitis C patients b… Review Anti-infective properties of the golden spice curcumin.	Botanical	Preclinical	Emerging	7	No indexed hits View evidence CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Curcumin Natural product Review Anti-infective properties of the golden spice curcumin. In Vitro Study Curcumin chitosan nanocomposite inhibited HCV-4a entry and replication… In Vitro Study, Viral Curcumin inhibits HCV replication by induction of heme oxygenase-1 and…	Food compound	Preclinical	Emerging	7	4 pubs View evidence CT.gov search · Cochrane · PubMed		PubChem
Alpha-Lipoic Acid Natural product Human Study A triple antioxidant approach to the treatment of hepatitis C may be su… Human Study A multi antioxidative treatment in chronic hepatitis C virus patients i… Animal Study, In Vitro Study Alpha-mangostin, piperine and beta-sitosterol as hepatitis C antivirus.	Nutraceutical	Preclinical	Emerging	7	3 pubs View evidence CT.gov search · Cochrane · PubMed		PubChem
Selenium Natural product Human Study A triple antioxidant approach to the treatment of hepatitis C may be su… Review Selenium, Selenoproteins, and Immunity	Nutraceutical	Phase III	Emerging	7	2 trials View evidence Registry trials NCT02215525 — Treatment of Chronic HCV Infected Egyptian Patients With Electromagnetic Waves and Herbal Therapy (UNKNOWN) PHASE3 NCT01355107 — Comparison of Selenium Levels in HCV- Infected Patients at Different Stages of Disease (COMPLETED) CT.gov search · Cochrane · PubMed		PubChem
Schisandra Natural product Human Study A multi antioxidative treatment in chronic hepatitis C virus patients i… Animal Study Schisandra fruit has a therapeutic effect in the treatment of hepatitis…	TCM herb	Preclinical	Emerging	7	—		—
Andrographis Natural product In Vitro Study Andrographis paniculata (Burm. F) Wall ex Nees: Antiviral properties In Vitro Study Andrographolide exerts anti-hepatitis C virus activity. In Vitro Study Evaluating andrographolide as a potent inhibitor of NS3-4A protease and…	Botanical	Preclinical	Emerging	7	—		PubChem
Quercetin Natural product Review Antiviral properties of flavonoids and delivery strategies. In Vitro Study Quercetin attenuates hepatitis C virus production.	Food compound	Phase I	Emerging	7	2 trials View evidence Registry trials NCT01438320 — Q-Trial in Patients With Hepatitis C (COMPLETED) PHASE1 NCT07487623 — Evaluation of the Hepatoprotective Effects of a Nutritional Supplement in Patients With Liver Disease Secondary to Chronic Hepatitis C Virus Infection (RESQUETI Study). (RECRUITING) NA CT.gov search · Cochrane · PubMed		PubChem
L-Carnitine Natural product Meta Analysis, Review Effect of L-carnitine supplementation on lipid profiles of patients wit…	Amino acid	Preclinical	Emerging	7	—		PubChem
Egcg Natural product Review Anti-infective potential of catechins and their derivatives against vir… In Vitro Study EGCG and delphinidin inhibit HCV entry by a new mechanism, by alteratio…	Food compound	Preclinical	Emerging	7	—		PubChem
Licorice Natural product Human Study A multi antioxidative treatment in chronic hepatitis C virus patients i… Human Study Long term administration of a licorice extract in the treatment of chro… Human Study Long term administration of a licorice extract in the treatment of chro…	Botanical	Preclinical	Emerging	2	—		—
Grassystatin a Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Faldaprevir Natural product Pharmacokinetics and Pharmacodynamics of Faldaprevir Following Multiple… Systematic Review and Network Meta-Analysis of Randomized Controlled Tr… ITPA Genotypes Predict Anemia but Do Not Affect Virological Response wi…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Delanzomib Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Bortezomib Natural product Successful treatment with bortezomib for refractory cryoglobulinemic va… Successful treatment by glecaprevir/pibrentasvir followed by hepatoprot… Hepatitis B Virus Reactivation: Risk Factors and Current Management Str…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Lisinopril Anhydrous Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Enalaprilat Anhydrous Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Captopril Natural product Side effects of the therapy with peginterferon and ribavirin in chronic… Angiotensin II activates I kappaB kinase phosphorylation of RelA at Ser… Angiotensin-converting enzyme inhibition attenuates the progression of…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Enalapril Natural product Transport of levovirin prodrugs in the human intestinal Caco-2 cell line	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Quinapril Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Quinaprilat Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Moexipril Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Eprosartan Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Irbesartan Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Valsartan Natural product Angiotensin Receptor Neprilysin Inhibitors for Hypertension and Protein… Challenges with Forecasting Budget Impact: A Case Study of Six ICER Rep… Combination Therapy with Ombitasvir/Paritaprevir/Ritonavir for Dialysis…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Tasosartan Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Losartan Potassium Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Spermine Natural product Hepatitis C Virus Dysregulates Polyamine and Proline Metabolism and Per… Synthesis, biological evaluation and mode of action studies of novel am… [Low-molecular-weight regulators of biogenic polyamine metabolism affec…	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
(2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)chroman-4-one Natural product	Food compound	Preclinical	Emerging	0	—	ClinicalTrials.gov	PubChem
Sophora Flavescens Natural product Human Study Kushenin, a flavonoid compound found within Sophora flavescens, inhibit… Human Study Preliminary study on therapeutic effect of oxymatrine in treating patie… In Vitro Study Oxymatrine has a similar efficacy to IFNalpha, but with no adverse effe…	Nutraceutical	Preclinical	Emerging	0	—		—
Lactoferrin Natural product Human Study Lactoferrin is a potential useful adjunct treatment for patients with c… Human Study Lactoferrin is one potential candidate as an anti‐HCV reagent that may… Human In Vitro Lactoferrin markedly inhibits hepatitis C virus infection in cultured h…	Food compound	Preclinical	Emerging	0	—		PubChem
Griffithsin Natural product Animal Study Activity of and effect of subcutaneous treatment with the broad-spectru… Animal Study, In Vitro Study Griffithsin has antiviral activity against hepatitis C virus. Animal Study Pharmacokinetics of the antiviral lectin griffithsin administered by di…	Nutraceutical	Preclinical	Emerging	0	—		—
Silibinin Natural product Human Study A lead in course with intravenous silibinin prior to the initiation of… Human Study Beneficial effects of silybin treatment after viral eradication in pati… Human Study Silibinin, a compound found within milk thistle, is well tolerated and…	Nutraceutical	Preclinical	Emerging	0	—		—
Phosphatidylcholine Natural product Human Study A mixture of milk thistle and phosphatidylcholine (LiverPro) has therap… Human Study The compound found in milk thistle known as silybin and soy phosphatidy… Human Study Treatment with a milk thistle (silybin), vitamin E and phospholipid for…	Nutraceutical	Preclinical	Emerging	0	—		—
EGCG (Epigallocatechin Gallate) Natural product Human Study Addition of epigallocatechin gallate 400 mg to sofosbuvir 400 mg + dacl… In Vitro Study EGCG and delphinidin inhibit HCV entry by a new mechanism, by alteratio…	Nutraceutical	Preclinical	Emerging	0	—		—
Artichoke Natural product Human Study Artichoke leave extract significantly improves fatigue and joint proble… Human Study Wild Egyptian artichoke exhibits strong antiviral activity against hepa… In Vitro Study Egyptian artichoke contained compounds that inhibited HCV infection in…	Nutraceutical	Preclinical	Emerging	0	—		—
Nigella Sativa (Aka Black Seed) Natural product Human Study Enhanced efficacy of direct-acting antivirals in hepatitis C patients b… In Vitro Study Alpha-zam selectively inhibits hepatitis C virus replication.	Nutraceutical	Preclinical	Emerging	0	—		—
Naringenin Natural product Animal Study, In Vitro Study Naringenin ameliorates insulin resistance by modulating endoplasmic ret… In Vitro Study A compound in grapefruit known as naringenin inhibits Hepatitis C virus. Review Antiviral properties of flavonoids and delivery strategies.	Food compound	Preclinical	Emerging	0	—		PubChem
Antioxidant Formulas Natural product Human Study A multi antioxidative treatment in chronic hepatitis C virus patients i… Human Study Antioxidant therapy is beneficial for chronic hepatitis C patients afte… Human Study A triple antioxidant approach to the treatment of hepatitis C may be su…	Nutraceutical	Preclinical	Emerging	0	—		—
Camel Milk Natural product Human Study Camel milk had a regulatory effect on multiple parameters of inflammato… Human Study A mixture of milk thistle and phosphatidylcholine (LiverPro) has therap… Human Study Silibinin, a compound found within milk thistle, is well tolerated and…	Nutraceutical	Preclinical	Emerging	0	—		—
Glycyrrhizin Natural product Animal Study "A glycyrrhizin-containing preparation reduces hepatic steatosis i… In Vitro Study Glycyrrhizin exhibits antiviral effects agent against Hepatitis C Virus.	Nutraceutical	Preclinical	Emerging	0	—		—
Pycnogenol (Pine Bark) Natural product Animal Study Dry birch bark extract can decrease the antigenic and infective activit… Transgenic Animal Study Inhibitory effects of Pycnogenol® on hepatitis C virus replication. In Vitro Study Pinus massoniana Lamb bark extract is effective for use in the stabiliz…	Nutraceutical	Preclinical	Emerging	0	—		—
Xanthohumol Natural product Animal Study Xanthohumol reduces liver damage and modulates oxidative reaction and a…	Nutraceutical	Preclinical	Emerging	0	—		—
Seaweed Natural product Review A comprehensive review of the antiviral potential of algal metabolites. In Vitro Study Seaweed polysaccharide extracts may be helpful in exploring further gat…	Nutraceutical	Preclinical	Emerging	0	—		—
Medicinal Mushrooms Natural product Animal Study Water-soluble extracts from edible mushrooms (Agaricus bisporus) as inh… Review Antiviral bioactive compounds of mushrooms and their antiviral mechanis… In Vitro Study Antiviral meroterpenoid rhodatin and sesquiterpenoids rhodocoranes A-E…	Nutraceutical	Preclinical	Emerging	0	—		—
Royal Jelly Natural product Review Antiviral potential of major royal jelly proteins. In Vitro Study Major royal-jelly protein 2 and its isoform X1 are two novel safe inhib…	Nutraceutical	Preclinical	Emerging	0	—		—
Rutin Natural product Review Antiviral properties of flavonoids and delivery strategies. In Vitro Study Identification of a flavonoid isolated from plum as a potent inhibitor…	Nutraceutical	Preclinical	Emerging	0	—		—
Blueberry Natural product Review In this review we presented an overview of functional foods and ingredi… In Vitro Study Proanthocyanidin from blueberry leaves suppresses expression of hepatit…	Nutraceutical	Preclinical	Emerging	0	—		—
Glutathione Natural product Human Study A multi antioxidative treatment in chronic hepatitis C virus patients i…	Nutraceutical	Preclinical	Emerging	0	—		—
Modified Arabinoxylan Rice Bran (Mgn-3) Natural product Human Study Arabinoxylan rice bran (Biobran) suppresses the viremia level in patien…	Nutraceutical	Preclinical	Emerging	0	—		—
Cannabis Natural product Human Study Cannabis use is associated with a lower insulin resistance risk in HIV-…	Nutraceutical	Preclinical	Emerging	0	—		—
Chlorella (Algae) Natural product Human Study Chlorella supplementation is safe and efficacious in adults with chroni…	Nutraceutical	Preclinical	Emerging	0	—		—
Cumin Natural product Human Study Enhanced efficacy of direct-acting antivirals in hepatitis C patients b… Review Anti-infective properties of the golden spice curcumin. In Vitro Study Curcumin chitosan nanocomposite inhibited HCV-4a entry and replication…	Nutraceutical	Preclinical	Emerging	0	—		—
Orange Natural product Human Study Orange juice was a convenient food in the diet of patients due to the i…	Nutraceutical	Preclinical	Emerging	0	—		—
Coffee Natural product Human Study Regular coffee consumption is associated with lower rates of disease pr…	Nutraceutical	Preclinical	Emerging	0	—		—
Testosterone Natural product Human Study Topical testosterone appears to increase muscle strength, stimulate alb…	Food compound	Preclinical	Emerging	0	—		PubChem
Beta Sitosterol Natural product Animal Study, In Vitro Study Alpha-mangostin, piperine and beta-sitosterol as hepatitis C antivirus. In Vitro Study Beta-caotene, vitamin D, linoleic acid possesses anti-hepatitis C virus…	Nutraceutical	Preclinical	Emerging	0	—		—
Mangosteen Natural product Animal Study, In Vitro Study Alpha-mangostin, piperine and beta-sitosterol as hepatitis C antivirus.	Nutraceutical	Preclinical	Emerging	0	—		—
Piperine Natural product Animal Study, In Vitro Study Alpha-mangostin, piperine and beta-sitosterol as hepatitis C antivirus.	Nutraceutical	Preclinical	Emerging	0	—		—
Barberry Natural product Animal Study Barberry ethanolic crude extract enriched-core-transduced DCs may serve…	Nutraceutical	Preclinical	Emerging	0	—		—
Celastrol Natural product Animal Study Celastrol attenuates hepatitis C virus translation and inflammatory res…	Nutraceutical	Preclinical	Emerging	0	—		—
Birch Natural product Animal Study Dry birch bark extract can decrease the antigenic and infective activit…	Nutraceutical	Preclinical	Emerging	0	—		—
Polyunsaturated Fatty Acids (PUFAs) Natural product Human Study Omega-3 fatty acids reduce fibrogenesis and increase responsiveness to… Animal Study n-3 PUFAs attenuated anti-viral CD8+ T cell responses against acute vir…	Nutraceutical	Preclinical	Emerging	0	—		—
Shiitake Mushroom Natural product Animal Study Vitamin D-enriched Shiitake mushroom exerts a synergistic anti-inflamma… Animal Study Water-soluble extracts from edible mushrooms (Agaricus bisporus) as inh… Review Antiviral bioactive compounds of mushrooms and their antiviral mechanis…	Nutraceutical	Preclinical	Emerging	0	—		—
Mushrooms: All Natural product Animal Study Water-soluble extracts from edible mushrooms (Agaricus bisporus) as inh… Review Antiviral bioactive compounds of mushrooms and their antiviral mechanis…	Nutraceutical	Preclinical	Emerging	0	—		—

Alterations and therapeutics are aggregated from public databases (Open Targets, HPO, ChEMBL, DGIdb, and others). Natural agents are candidates from OSMF narrative reviews on opensourcemed.info/chronic-disease.html — not approved treatments. This page is for research orientation only — not medical advice.